

# Maternal underweight and obesity are associated with placental pathologies in human pregnancy.

Hailey Scott<sup>a</sup>, David Gynspan<sup>b</sup>, Laura N Anderson<sup>c</sup>, Kristin L Connor<sup>a,1</sup>

<sup>a</sup> Department of Health Sciences, Carleton University

<sup>b</sup> Department of Pathology and Laboratory Medicine, University of British Columbia

<sup>c</sup> Health Research Methods, Evidence, and Impact, McMaster University

<sup>1</sup> Correspondence:

Dr. Kristin Connor

Department of Health Sciences, Carleton University, Ottawa, Ontario, Canada, K1S5B6

E: [kristin.connor@carleton.ca](mailto:kristin.connor@carleton.ca), Tel.: +1 613-520-2600 ext. 4202

## Abstract

**Introduction:** Maternal underweight and obesity are prevalent conditions, associated with chronic, low-grade inflammation, poor fetal development, and long-term adverse outcomes for the child. The placenta senses and adapts to the pregnancy environment in an effort to support optimal fetal development. However, the mechanisms driving these adaptations, and the resulting placental phenotypes, are poorly understood. We hypothesised that maternal underweight and obesity would be associated with increased prevalence of placental pathologies in term and preterm pregnancies.

**Methods:** Data from 12,154 pregnancies were obtained from the Collaborative Perinatal Project, a prospective cohort study conducted from 1959 to 1974. Macro and microscopic placental pathologies were analysed across maternal prepregnancy body mass index (BMI) to assess differences in the presence of pathologies among underweight, overweight, and obese BMI groups compared to normal weight reference BMI at term and preterm. Placental pathologies were also assessed across fetal sex.

**Results:** Pregnancies complicated by obesity had placentae with increased fetal inflammation at preterm, and increased inflammation of maternal gestational tissues at term. In term pregnancies, increasing maternal BMI associated with increased maternal vascular malperfusion (MVM), odds of an appropriately mature placenta for gestational age, and placental weight, and decreased placental efficiency. Male placentae, independent of maternal BMI, had increased inflammation, MVM, and placental efficiency than female placentae, particularly at term.

**Discussion:** Maternal underweight and obesity are not inert conditions for the placenta, and the histomorphological changes driven by suboptimal maternal BMI may serve as indicators of adversities experienced *in utero* and potential predictors of future health trajectories.

**Keywords:** Underweight, obesity, placental pathology, inflammation, Collaborative Perinatal Project

## Introduction

Maternal underweight and obesity are global health burdens; maternal underweight remains a persisting problem, and the prevalence of obesity in pregnancy continues to rise<sup>1-3</sup>. Both conditions have been associated with higher levels of inflammation in the mother, which favour increased inflammation in the placenta<sup>4</sup>, suboptimal nutrient availability to the fetus<sup>4</sup>, and adverse pregnancy and offspring outcomes<sup>5,6</sup>. Yet, the mechanisms that drive these outcomes remain poorly understood.

The placenta is a critical regulator of the fetal environment and can adapt to mitigate harmful exposures, or maladapt to permit their adverse effects<sup>7</sup>. For example, inflammation can reduce placental area<sup>8</sup> and impair spiral artery remodelling<sup>9</sup>, which can affect nutrient and gas exchange<sup>8-11</sup> with potential consequences for the developing offspring<sup>12-14</sup>. Additionally, there is some evidence that maternal underweight and obesity may be unfavourable for placental development. Maternal obesity has been associated with chronic villitis<sup>15,16</sup>, both delayed and accelerated placental villous maturation<sup>16</sup>, and increased atheromas and villous infarcts<sup>16,17</sup>, pathologies which have been linked to placental insufficiency<sup>18</sup>, fetal growth restriction, and neurodevelopmental

impairment<sup>16</sup>. The effects of maternal undernutrition or low BMI on placental pathologies are less well documented<sup>19</sup>. Animal models of undernutrition have shown evidence of abnormal placental vasculature and decreased fetal blood space, labyrinth, and junctional zone area<sup>19</sup>, which may impair placental transfer<sup>20</sup>. The pro-inflammatory state induced by maternal underweight and obesity may also directly influence placental function, for example through altered expression of placental nutrient transporters<sup>21-23</sup>. Thus, to regulate the fetal environment, the placenta senses and integrates signals from the maternal environment, which may impact placental pathology. One mechanism through which the placenta may sense changes in maternal pathophysiology associated with suboptimal maternal BMI is mechanistic/mammalian target of rapamycin (mTOR), to regulate nutrient transport and subsequently, fetal growth<sup>24,25</sup>. Maternal obesity has been shown to activate placental mTOR, associated with increased fetal growth<sup>26</sup>, while conversely, intrauterine growth restriction, linked to maternal underweight<sup>27</sup>, has been associated with reduced placental mTOR signalling activity<sup>28</sup>. This suggests that the placenta integrates multiple signals, including those indicative of maternal supply and fetal demand, to regulate nutrient transfer and fetal growth<sup>29</sup>. Further, suboptimal maternal BMI is associated with altered metabolic status, and maternal obesity associates

with dysregulated levels of metabolic hormones, including leptin and insulin, that are known to be upstream regulators of placental mTOR, and can influence placental nutrient transport<sup>26</sup>. The low-grade, pro-inflammatory state associated with maternal obesity may also alter placental outcomes, through increased placental levels of pro-inflammatory cytokines<sup>30-32</sup>, placental immune cells<sup>31</sup>, and activation of innate immune signalling pathways<sup>32-34</sup>, potentially mediating inflammatory signals between the mother, placenta, and fetus in pregnancies complicated by suboptimal maternal BMI.

However, given the multifactorial pathophysiology associated with suboptimal maternal BMI, including inflammatory, metabolic, and vascular factors<sup>35,36</sup>, reflected pathological phenotypes may vary. Even in the absence of overt adverse outcomes, such as large or small for gestational age infants or preterm birth<sup>37</sup>, changes to placental morphology and function (even subtle) may still have lasting effects on offspring health trajectories<sup>38,39</sup>. Therefore, it is important to understand even subtle placental phenotypes in these common conditions, as placental structural and functional adaptations may serve as a record of adversities experienced *in utero*, and could help reveal the mechanisms through which these adversities affect the developing offspring. However, the placental morphological and histopathologic changes induced by maternal underweight and obesity, in the absence of other major comorbidities or adverse perinatal events, are poorly characterized.

We hypothesised that, compared to women of normal weight, maternal underweight and obesity prepregnancy would be associated with increased prevalence of placental pathologies in term and preterm pregnancies, and that there would be differences in pathology prevalence based on placental sex. Using data from the Collaborative Perinatal Project (CPP), our primary objective was to determine whether placental pathologies were more prevalent in term and preterm pregnancies complicated by suboptimal maternal prepregnancy BMI. Our findings help to quantify placental pathologies in common pregnancy conditions, and uncover the mechanisms linking poor maternal metabolic health with suboptimal fetal growth and development.

## Methods

### *Study design and population*

Secondary data analysis was conducted using data from the CPP, a prospective cohort study designed to identify relationships between pregnancy and perinatal risk factors and child outcomes (<https://catalog.archives.gov/id/606622>). The CPP was conducted from 1959 to 1974 at 12 hospitals across the United States, and collected pregnancy data through the prenatal period and delivery, and child outcomes for approximately 58,000 pregnancies<sup>40</sup>.

The primary exposure of interest was maternal prepregnancy BMI, specifically maternal underweight, overweight, and obesity, compared to normal weight as the reference category. BMI was classified according to the World Health Organization and American College of Obstetricians and Gynecologists guidelines, where maternal BMI is categorized as underweight (<18.5), normal weight (18.5–24.9), overweight (25–29.9), or obese ( $\geq 30$ ). To evaluate the associations between maternal BMI and placental pathologies, the study sample was restricted to pregnancies with placental pathology data available, and maternal height and prepregnancy weight available to calculate maternal prepregnancy BMI. We included only singleton births from first pregnancies (parity and gravidity of zero),


where fetal sex was documented as male or female. Gestational age below 24 weeks or above 43 weeks were excluded based on the limit of viability<sup>41</sup>, and due to morphological changes to the placenta such as those induced by cellular senescence<sup>42</sup>, and increased risk for fetal complications in post-term pregnancies<sup>43</sup>. The CPP calculated gestational age based on the last menstrual period to the nearest week. These selection criteria resulted in a sample of 12,154 pregnancies (Supplementary Figure 1).

### *Placental pathologies*


The primary outcomes were macroscopic and microscopic placental pathologies (Figure 1). Macroscopic data included placental weight, largest and smallest diameter, thickness, and placental shape. Infant birthweight to placental weight/largest diameter/smallest diameter/thickness ratios were calculated as potential predictors of placental efficiency<sup>38,44</sup>. The top and bottom 0.5% of raw infant and placental anthropometry data (birthweight, placental weight, and placental dimensions) were excluded to remove biologically implausible data. The umbilical cord was assessed for cord edema and number of vessels, given the increased incidence of a single artery cord with gestational diabetes mellitus (GDM)<sup>45</sup>, a covariate of interest for pregnancies with obesity. Thrombosed fetal vessels and cut surface infarcts were assessed, which may be associated with impaired placental perfusion<sup>46</sup>. For microscopic variables: decidual vessel fibrinoids and atheroma were included, features of malperfusion<sup>47</sup>. Neutrophilic infiltration of the umbilical vein, umbilical artery, cord substance, chorion and amnion membranes, and chorion and amnion of the (fetal side) placental surface were also obtained, which may be indicative of ascending maternal infection<sup>48</sup>. Cut surface calcification was included as an indicator for placental maturation<sup>49</sup>. Syncytium-nuclear clumping, or syncytial knots, and stromal fibrosis are signs of accelerated villous maturation and were thus included<sup>50</sup>. Presence of Langhans' layer, Hofbauer cells, and pathological edema were included as indicators of placental immaturity<sup>51,52</sup>. A variable provided for the apparent maturity of the placenta was also included as a marker for appropriate placental development for gestational age. For multivariable analyses, categorical placental pathology variables were collapsed into binary categories (Supplementary Table 1).

We derived additional summary scores for placental inflammation, maternal vascular malperfusion (MVM), and placental immaturity. A maternal inflammation summary score was derived from the following variables: opacity of membranes and neutrophil infiltration of the amnion and chorion membranes and of the placental surface. Where data were available for all constituent variables, the individual variable scores were summed to create a composite score ranging from zero to fourteen, where a higher score represents increased levels of inflammation. Similarly, a fetal inflammation summary score was derived from neutrophilic infiltration of the umbilical vein, artery, and cord substance to create a composite score from zero to nine. A summary score considering features of MVM was derived from: presence of infarcts and syncytium-nuclear clumping to create a score ranging from zero to two, where a higher score indicates increased MVM. A placental immaturity score was derived from the following variables: presence of Langhans' layer, Hofbauer cells, absence of stromal fibrosis, and normal or less than normal syncytium-nuclear clumping, to create a score ranging from zero to four where a higher score indicates a more immature placental phenotype (Supplementary Table 2).

A



B



**Figure 1. Prevalence of placental pathologies in term (A) and preterm (B) pregnancies.** The presence or absence of categorical placental pathologies across maternal prepregnancy body mass index (BMI) groups, where mothers were categorized as underweight (UW), normal weight (NW), overweight (OW) or having obesity (OB), in term (n=10,415; panel A) and preterm (n=1,739; panel B) pregnancies.

## Maternal demographics

Our primary exposure of interest, maternal prepregnancy BMI, was defined based on measured height and self-reported prepregnancy weight collected at study enrollment. In addition to prepregnancy BMI, maternal demographic data including age, race, education, marital status, income, socioeconomic index, housing density, smoking history, diabetes mellitus status, and gestational weight gain were obtained. The socioeconomic index is a composite numerical index derived from scores for education (of the head of household/chief earner), occupation (of the head of household/chief earner), and family income, ranging from 0.0–9.5, where 9.5 represents the highest socioeconomic status<sup>53</sup>. Smoking history was provided as the number of cigarettes smoked per day at the time of the interview, from zero cigarettes (including non-smokers) to 60 cigarettes per day. Additional smoking categories included 61 or more cigarettes per day, regular smoker but less than one cigarette per day, and irregular smoker but less than four cigarettes per month. Smoking history was presented as non-smokers (including women currently smoking zero cigarettes per day), light smokers (less than one pack of 20 cigarettes per day), and heavy smokers (one or more packs of 20 cigarettes per day). Diabetes mellitus was presented as presence or absence, where presence included diabetes mellitus reported before pregnancy, during pregnancy, both before and during, during and postpartum, or before, during, and postpartum. Based on current recommendations from the Institute of Medicine (IOM) guidelines (2009), maternal weight gain was categorized as inadequate, adequate, or excessive for singleton pregnancies based on prepregnancy BMI, where the recommended weight gain ranges are 28–40 pounds, 25–35 pounds, 15–25 pounds or 11–20 pounds<sup>54</sup> for mothers who are underweight, normal weight, overweight, or have obesity, respectively.

## Statistical analyses

### Univariate analyses

Univariate analysis was conducted to evaluate differences in the prevalence of placental pathologies across maternal prepregnancy BMI groups. Given that the presence of some placental pathologies are dependent on gestational age<sup>55</sup>, we conducted all analyses stratified for term and preterm placentae. Differences between maternal BMI groups and placental measures were determined by Kruskal–Wallis test with Steel–Dwass *post hoc* for continuous nonparametric data, and Likelihood Ratio Chi Square test for categorical data. Placental pathologies were also assessed across fetal sex. Data are presented as median (interquartile range) and Wilcoxon test effect size ( $r$ ) (95% confidence interval; CI) for non-parametric continuous data, and frequency (percentage) and Cramer’s  $V$  effect size (95% CI) or odds ratio (95% CI) (for binary fetal sex analyses) for categorical variables. Statistical significance was defined as  $p < 0.05$ . Data were analysed using JMP statistical software (14.0), and Wilcoxon test effect size and Cramer’s  $V$  effect size were calculated in R (4.1.2).

### Multivariable analyses

We performed multivariable logistic and linear regression to determine the relationships between maternal prepregnancy BMI and placental pathologies at term and preterm. Logistic regression models were used to determine the associations between maternal BMI (continuous) and binary placental pathologies. Categorical placental pathology variables were collapsed into binary categories to calculate odds ratios for the pathological phenotype. Any data coded as unknown, unable to

determine, or missing were excluded from regression analyses. Data are presented as unadjusted (OR) or adjusted units odds ratio (aOR) (95% CI). Linear regression models were used to determine the associations between maternal BMI (continuous) and continuous placental pathology variables. Data are reported as adjusted beta coefficient ( $\beta$ ) (95% CI). Covariates of interest were identified a priori and included fetal sex (male/female), maternal race (White, Black, and Other), maternal age (continuous), smoking history (non-smoker, light smoker, heavy smoker), maximum gestational weight gain (continuous), diabetes (yes/no), maternal education (continuous), and socioeconomic index (continuous). Two regression models were defined a priori: 1) An unadjusted model was first used to identify the associations between prepregnancy BMI alone (as a continuous variable) with placental pathologies and 2) an adjusted model adjusted for the covariates defined above.

## Results

### Maternal demographics differed across maternal BMI groups

Maximum gestational weight gain among preterm (Wilcoxon test effect size,  $r = -0.09$  [-0.14 to -0.04]) and term ( $r = -0.05$  [-0.07 to -0.03]) pregnancies was greatest in underweight and lowest in obese BMI groups (Supplementary Tables 3–4). However, according to IOM (2009) guidelines, weight gain in underweight pregnancies was still inadequate at preterm and term, while most pregnancies with obesity had either inadequate or excessive weight gain at preterm, and excessive weight gain at term (Supplementary Tables 3–4). Maternal age, race, education, marital status, income, socioeconomic index, and housing density also differed by BMI group (Supplementary Tables 3–4). There were no differences in median maternal prepregnancy BMI across study years (based on date of delivery,  $p = 0.10$ ). The median BMI from 1959 to 1966 ranged from 20.9 (in years 1960, 1962, 1963, 1966) to 21.3 (in 1959; Supplementary Figure 2). Socioeconomic index varied by study site ( $p < 0.0001$ ); across the 12 study sites, median socioeconomic index ranged from 3.0, relatively low on the socioeconomic index scale ranging from 0.0 to 9.5 (Virginia; Tennessee; Louisiana locations) to 8.3, a relatively high socioeconomic index score (Buffalo, New York location; Supplementary Table 5). There was no association between maternal BMI and socioeconomic index at preterm, but at term, socioeconomic index was highest among term normal weight pregnancies compared to all other BMI groups ( $p < 0.0001$ , Supplementary Table 4).

### Maternal obesity associated with increased neutrophil infiltration of gestational tissues

Among preterm pregnancies, fetal inflammation, characterised by the composite fetal inflammation summary score, was greater in placentae from mothers with obesity compared to underweight and normal weight BMI groups ( $r = 0.009$  [-0.04 to 0.06], Table 1). There were no effects of maternal BMI group on neutrophil infiltration in the preterm membranes or placental surface. Neutrophil infiltration of the umbilical vein (aOR=1.06 [1.01–1.12]), umbilical cord substance (aOR=1.08 [1.02–1.14]), and amnion membrane (OR=1.05 [1.01–1.10]), but not the umbilical artery, chorion membrane, or amnion and chorion of the placenta, were more likely with increasing maternal BMI (Table 2).

**Table 1.** Associations between maternal prepregnancy BMI and microscopic placental pathologies in preterm pregnancies, N=1739.

Placental pathology	Pregpregnancy BMI				p-value	Effect size
	UW (n=259)	NW (n=1287)	OW (n=155)	OB (n=38)		
<b>Cord</b>						
Neutrophil infiltration, umbilical vein					0.14	0.06 (0.00–0.07)
Not seen	222 (85.7)	1127 (87.6)	129 (83.2)	27 (71.1)		
Slight	15 (5.79)	71 (5.52)	13 (8.39)	6 (15.8)		
Moderate	0	3 (0.23)	0	0		
Marked	7 (2.70)	48 (3.73)	10 (6.45)	3 (7.89)		
Unknown/missing	15 (5.79)	38 (2.95)	3 (1.94)	2 (5.26)		
Neutrophil infiltration, umbilical artery					0.62	0.04 (0.00–0.05)
Not seen	228 (88.0)	1165 (90.5)	142 (91.6)	30 (78.9)		
Slight	9 (3.47)	45 (3.50)	3 (1.94)	3 (7.89)		
Moderate	0	1 (0.08)	0	0		
Marked	7 (2.70)	37 (2.87)	7 (4.52)	3 (7.89)		
Unknown/missing	15 (5.79)	39 (3.03)	3 (1.94)	2 (5.26)		
Neutrophil infiltration, cord substance					0.23	0.05 (0.00–0.07)
Not seen	233 (90.0)	1160 (90.1)	140 (90.3)	29 (76.3)		
Slight	8 (3.09)	58 (4.51)	6 (3.87)	5 (13.2)		
Moderate	0	2 (0.16)	0	0		
Marked	3 (1.16)	28 (2.18)	6 (3.87)	2 (5.26)		
Unknown/missing	15 (5.79)	39 (3.03)	3 (1.94)	2 (5.26)		
Fetal inflammation summary score	0 (0, 0) <sup>A</sup>	0 (0, 0) <sup>A</sup>	0 (0, 0) <sup>AB</sup>	0 (0, 1) <sup>B</sup>	<b>0.002</b>	0.009 (-0.04 to 0.06)
<b>Membranes</b>						
Neutrophil infiltration, membrane, amnion					0.21	0.08 (0.03–0.10)
Not seen	208 (80.3)	1075 (83.5)	126 (81.3)	29 (76.3)		
Slight	21 (8.11)	74 (5.75)	13 (8.39)	5 (13.2)		
Moderate	0	1 (0.08)	0	1 (2.63)		
Marked	5 (1.93)	33 (2.56)	6 (3.87)	1 (2.63)		
Unknown/missing	25 (9.65)	104 (8.08)	10 (6.45)	2 (5.26)		
Neutrophil infiltration, membrane, chorion					0.70	0.04 (0.00–0.05)
Not seen	197 (76.1)	1006 (78.2)	114 (73.5)	27 (71.1)		
Slight	27 (10.4)	140 (10.9)	20 (12.9)	3 (7.89)		
Moderate	1 (0.39)	1 (0.08)	0	0		
Marked	18 (6.95)	103 (8.00)	16 (10.3)	6 (15.8)		
Unknown/missing	16 (6.18)	37 (2.87)	5 (3.23)	2 (5.26)		
Neutrophil infiltration, placental surface, amnion					0.61	0.04 (0.00–0.05)
Not seen	208 (80.3)	1063 (82.6)	126 (81.3)	31 (81.6)		
Slight	16 (6.18)	58 (4.51)	8 (5.16)	3 (7.89)		
Moderate	0	1 (0.08)	0	0		
Marked	6 (2.32)	25 (1.94)	8 (5.16)	1 (2.63)		
Unknown/missing	29 (11.2)	140 (10.9)	13 (8.39)	3 (7.89)		
Neutrophil infiltration, placental surface, chorion					0.44	0.04 (0.00–0.06)
Not seen	206 (79.5)	1061 (82.4)	127 (81.9)	29 (76.3)		
Slight	26 (10.0)	119 (9.25)	10 (6.45)	5 (13.2)		
Moderate	0	0	0	0		
Marked	12 (4.63)	67 (5.21)	14 (9.03)	2 (5.26)		
Unknown/missing	15 (5.79)	40 (3.11)	4 (2.58)	2 (5.26)		
Maternal inflammation summary score	0 (0, 1)	0 (0, 1)	0 (0, 1.25)	0 (0, 2)	0.38	0.006 (-0.04 to 0.06)

Decidua						
Decidual vessels, fibrinoid					0.25	0.05 (0.00–0.09)
Not seen	225 (86.9)	1159 (90.1)	139 (89.7)	35 (92.1)		
Present	15 (5.79)	55 (4.27)	3 (1.94)	1 (2.63)		
Unable to determine/unknown/missing	19 (7.34)	73 (5.67)	13 (8.39)	2 (5.26)		
Decidual vessels, atheroma					0.13	0.05 (0.00–0.09)
Not seen	234 (90.3)	1194 (92.8)	142 (91.6)	36 (94.7)		
Present	5 (1.93)	16 (1.24)	0	0		
Unable to determine/unknown/missing	20 (7.72)	77 (5.98)	13 (8.39)	2 (5.26)		
Syncytium, nuclear clumping					1.0	0.01 (0.02–0.07)
Normal	183 (70.7)	956 (74.3)	114 (73.5)	28 (73.7)		
Less than normal for term placenta	52 (20.1)	256 (19.9)	32 (20.6)	7 (18.4)		
Excessive for term placenta	10 (3.86)	42 (3.26)	6 (3.87)	1 (2.63)		
Excessive in parts	0	0	0	0		
Unable to determine/unknown/missing	14 (5.41)	33 (2.56)	3 (1.94)	2 (5.26)		
Maternal vascular malperfusion summary score	0 (0, 0)	0 (0, 0)	0 (0, 0.5)	0 (0, 0.25)	0.79	0.004 (-0.05 to 0.05)
Terminal villi						
Langhans' layer					0.24	0.04 (0.00–0.08)
Not seen	234 (90.3)	1218 (94.6)	146 (94.2)	36 (94.7)		
Present	11 (4.25)	36 (2.80)	6 (3.87)	0		
Unknown/missing	14 (5.41)	33 (2.57)	3 (1.94)	2 (5.26)		
Hofbauer cells					0.11	0.06 (0.00–0.10)
Few	227 (87.6)	1177 (91.4)	135 (87.1)	35 (92.1)		
Many	18 (6.95)	77 (5.99)	17 (11.0)	1 (2.63)		
Unknown/missing	14 (5.41)	33 (2.56)	3 (1.94)	2 (5.26)		
Stromal fibrosis					0.58	0.03 (0.00–0.07)
Not seen	231 (89.2)	1201 (93.3)	142 (91.6)	35 (92.1)		
Present	14 (5.41)	53 (4.12)	9 (5.81)	1 (2.63)		
Unable to determine/unknown/missing	14 (5.41)	33 (2.56)	4 (2.58)	2 (5.26)		
Pathological edema					0.57	0.04 (0.00–0.07)
Not seen	230 (88.8)	1200 (93.2)	144 (92.9)	35 (92.1)		
Present	15 (5.79)	53 (4.12)	8 (5.16)	1 (2.63)		
Unable to determine/unknown/missing	14 (5.41)	34 (2.64)	3 (1.94)	2 (5.26)		
Intervillous space						
Apparent maturity of placenta					0.62	0.04 (0.00–0.04)
Under 20 weeks	0	4 (0.31)	0	0		
20-27 weeks	11 (4.24)	34 (2.64)	5 (3.23)	2 (5.26)		
28-36 weeks	57 (22.0)	260 (20.2)	27 (17.4)	6 (15.8)		
37 weeks or over	177 (68.3)	952 (74.0)	119 (76.8)	28 (73.7)		
Unable to determine/unknown/missing	14 (5.41)	37 (2.87)	4 (2.58)	2 (5.26)		
Immaturity summary score	2 (2, 2)	2 (2, 2)	2 (2, 2)	2 (2, 2)	0.80	0.0008 (-0.05 to 0.05)

Data are median (IQR; Kruskal-Wallis/Wilcoxon test for non-parametric data with Steel-Dwass *post-hoc*) for continuous variables or n (%) (Likelihood Ratio Chi Square test) for categorical variables. \* $p < 0.05$ . Post hoc differences between groups are denoted by different letters. Effect sizes are Wilcoxon test effect size ( $r$ ) (95% CI) for continuous variables, or Cramer's  $V$  (95% CI) for categorical variables. UW = underweight. NW = normal weight. OW = overweight. OB = obese.

**Table 2.** Multivariable analyses for associations between maternal prepregnancy BMI (continuous) and microscopic placental pathologies in preterm pregnancies, N=1739.

Placental pathology	Unadjusted model			Adjusted model		
	$\beta$ (95% CI)	OR (95% CI)	p-value	$\beta$ (95% CI)	OR (95% CI)	p-value
<b>Cord neutrophil infiltration</b>						
Umbilical vein Not seen Any degree of infiltration	0.07 (0.03–0.12)	1.08 (1.03–1.12)	***	0.06 (0.01–0.11)	1.06 (1.01–1.12)	**
Umbilical artery Not seen Any degree of infiltration	0.05 (-0.003 to 0.10)	1.05 (1.00–1.11)	NS	0.04 (-0.02 to 0.10)	1.04 (0.98–1.10)	NS
Umbilical cord substance Not seen Any degree of infiltration	0.08 (0.03–0.13)	1.09 (1.03–1.14)	**	0.08 (0.02–0.13)	1.08 (1.02–1.14)	**
Fetal inflammation score	0.04 (0.01–0.06)	-	**	0.03 (0.003–0.05)	-	*
<b>Membranes neutrophil infiltration</b>						
Membrane roll, amnion Not seen Any degree of infiltration	0.05 (0.006–0.10)	1.05 (1.01–1.10)	*	0.03 (-0.02 to 0.08)	1.03 (0.98–1.09)	NS
Membrane roll, chorion Not seen Any degree of infiltration	0.03 (-0.004 to 0.07)	1.03 (1.00–1.07)	NS	0.02 (-0.02 to 0.06)	1.02 (0.98–1.06)	NS
Placental surface, amnion Not seen Any degree of infiltration	0.03 (-0.02 to 0.09)	1.04 (0.98–1.09)	NS	0.02 (-0.04 to 0.07)	1.02 (0.96–1.08)	NS
Placental surface, chorion Not seen Any degree of infiltration	0.03 (-0.01 to 0.07)	1.03 (0.99–1.07)	NS	0.01 (-0.03 to 0.05)	1.01 (0.97–1.06)	NS
Maternal inflammation score	0.04 (0.0006–0.08)	-	*	0.02 (-0.02 to 0.07)	-	NS
<b>Decidua</b>						
Decidual vessels, fibrinoid Not seen Present	-0.03 (-0.11 to 0.04)	0.97 (0.89–1.05)	NS	-0.05 (-0.13 to 0.04)	0.96 (0.88–1.04)	NS
Decidual vessels, atheroma Not seen Present	-0.10 (-0.26 to 0.07)	0.91 (0.77–1.07)	NS	-0.12 (-0.31 to 0.07)	0.89 (0.73–1.07)	NS
Syncytium, nuclear clumping Normal/ < normal for term Excessive/in parts for term	-0.01 (-0.10 to 0.07)	0.99 (0.91–1.07)	NS	-0.03 (-0.12 to 0.06)	0.97 (0.88–1.06)	NS
Maternal vascular malperfusion	0.006 (-0.001 to 0.01)	-	NS	0.005 (-0.002 to 0.01)	-	NS
<b>Terminal villi</b>						
Langhans' layer Not seen Present	-0.02 (-0.11 to 0.07)	0.98 (0.89–1.07)	NS	-0.04 (-0.14 to 0.06)	0.96 (0.87–1.07)	NS
Hofbauer cells Few Many	0.03 (-0.03 to 0.09)	1.03 (0.97–1.09)	NS	0.02 (-0.04 to 0.08)	1.02 (0.96–1.09)	NS

Stromal fibrosis	0.02 (-0.05 to 0.09)	1.02 (0.95–1.09)	NS	-0.004 (-0.08 to 0.07)	1.00 (0.93–1.07)	NS
Not seen						
Present						
Pathological edema	0.01 (-0.06 to 0.08)	1.01 (0.94–1.08)	NS	0.02 (-0.06 to 0.09)	1.02 (0.94–1.10)	NS
Not seen						
Present						
Intervillous space						
Apparent maturity of placenta	0.02 (-0.02 to 0.05)	1.02 (0.98–1.05)	NS	0.02 (-0.02 to 0.06)	1.02 (0.98–1.07)	NS
Appropriate mature						
Hyper-mature						
Immaturity summary score	0.0006 (-0.006 to 0.007)	-	NS	0.002 (-0.005 to 0.009)	-	NS

Data are  $\beta$  (95% CI) and unit odds ratios (95% CI) for presence of pathology from Logistic regression models with p-value from Likelihood Ratio Chi Square test for categorical variables, or  $\beta$  (95% CI) with p-value from Standard Least Squares models for continuous variables. The adjusted model includes fetal sex, maternal race, maternal age, smoking history, maternal education, socioeconomic status, gestational weight gain, and maternal diabetes mellitus status. NS (not significant):  $p>0.05$ ; \* $p\leq 0.05$ ; \*\* $p\leq 0.01$ ; \*\*\* $p\leq 0.001$ ; \*\*\*\* $p\leq 0.0001$ .

Among term pregnancies, pregnancies complicated by obesity had the greatest percentage of marked neutrophil infiltration of the umbilical vein and artery, amnion and chorion membranes, and amnion, but not chorion, of the placental surface (Table 3). The maternal inflammation summary score was greatest among pregnancies complicated by obesity, though there were no differences between BMI groups on post hoc analysis ( $r=0.008$  [-0.01 to 0.03], Table 3). Further, neutrophilic infiltration of the umbilical vein (aOR=1.03 [1.01–1.05]), artery (aOR=1.04 [1.00–1.07]), and cord substance (aOR=1.04 [1.01–1.07]) increased with increasing BMI (Table 4). Neutrophil infiltration of the amnion membrane (aOR=1.06 [1.03–1.08]), chorion membrane (aOR=1.04 [1.02–1.06]), amnion of the placental surface (aOR=1.04 [1.01–1.07]), and chorion of the placental surface (aOR=1.04 [1.02–1.06]) were also greater with increasing BMI (Table 4).

#### **Higher maternal BMI associated with MVM among term pregnancies**

At term, increasing maternal BMI was associated with greater odds of an appropriately mature placenta based on apparent maturity of the placenta (aOR=0.94 [0.92–0.97]) and increased MVM (a $\beta$ =0.007 [0.004–0.01], Table 4), and placenta from mothers with obesity had the greatest percentage of thrombosed fetal vessels compared to all other BMI groups (Cramer's  $V=0.03$  [0.004–0.05], Supplementary Table 6). Additionally, presence of infarcts alone was more likely as maternal BMI increased (aOR=1.03 [1.02–1.05], Supplementary Table 7). There were no differences in apparent placental maturity or vasculature-related pathologies by BMI among preterm pregnancies (Table 1).

#### **Both maternal underweight and increased BMI influenced placental anthropometry**

In preterm pregnancies where mothers were underweight, placental weight was reduced compared to placenta from mothers with overweight and obesity ( $r=0.04$  [-0.004 to 0.09]), and smallest diameter was reduced compared to placenta from pregnancies complicated by obesity ( $r=0.06$  [0.01–0.11], Supplementary Table 8), but there were no differences in placental anthropometry compared to normal weight BMI. Among term pregnancies where mothers were underweight, placental weight ( $r=0.08$  [0.06–0.10])

and smallest diameter ( $r=0.05$  [0.03–0.07]) were reduced compared to all other BMI groups, with most prominent differences between the underweight and obese groups (Supplementary Table 6). At term only, birthweight to placental weight ratio was higher in mothers who were underweight compared to overweight, but not different than normal weight ( $r=-0.03$  [-0.05 to -0.006], Supplementary Table 6). Similarly, when considering BMI as a continuous variable, placental weight and smallest diameter increased with increasing maternal BMI among preterm and term pregnancies, and birthweight to placental weight ratio decreased with increasing maternal BMI at term (Supplementary Tables 7,9).

#### **Fetal sex influenced placental pathology**

Among preterm pregnancies, female placenta had a greater fetal inflammation summary score than male placenta ( $r=-0.05$  [-0.10 to -0.004], Table 5), but there were no sex differences in neutrophil infiltration of the membranes or placental surface. Male term placenta had greater fetal and maternal placental inflammation, including neutrophil infiltration of the umbilical vein, umbilical cord substance, amnion membrane, chorion membrane, amnion of the placenta, chorion of the placenta, and fetal and maternal inflammation summary scores (Table 5). Further, when considering only pregnancies with maternal obesity, at term, male placenta had greater neutrophil infiltration of the umbilical vein and chorion membrane than female placenta (Supplementary Figure 3).

Female preterm placenta had increased syncytium-nuclear clumping (OR=0.53 [0.31–0.91], Table 5), but there were no differences in presence of infarcts or MVM summary score between sexes preterm. Male term placenta had increased MVM ( $r=0.04$  [0.02–0.06], Table 5) and placental infarcts compared to female placenta (OR=1.22 [1.11–1.33], Table 6). Infant birthweight to placental weight ratio was also increased in males compared to females at preterm ( $r=0.07$  [0.03–0.12]) and term ( $r=0.07$  [0.05–0.09], Table 6).



**Table 3.** Associations between maternal prepregnancy BMI and microscopic placental pathologies in term pregnancies, N=10,415.

Placental pathology	Prepregnancy BMI				p-value	Effect size
	UW (n=1201)	NW (n=8022)	OW (n=912)	OB (n=280)		
<b>Cord</b>						
Neutrophil infiltration, umbilical vein					<b>0.001</b>	0.03 (0.01–0.04)
Not seen	1065 (88.7)	6965 (86.8)	787 (86.3)	236 (84.3)		
Slight	84 (6.99)	604 (7.53)	51 (5.59)	22 (7.86)		
Moderate	0	16 (0.20)	0	0		
Marked	24 (2.0)	198 (2.47)	35 (3.84)	15 (5.36)		
Unknown/missing	28 (2.33)	239 (2.98)	39 (4.28)	7 (2.50)		
Neutrophil infiltration, umbilical artery					0.05	0.03 (0.006–0.03)
Not seen	1141 (95.0)	7563 (94.3)	840 (92.1)	259 (92.5)		
Slight	20 (1.67)	142 (1.77)	16 (1.75)	5 (1.79)		
Moderate	0	3 (0.04)	0	0		
Marked	12 (1.0)	75 (0.93)	18 (1.97)	9 (3.21)		
Unknown/missing	28 (2.33)	239 (2.98)	38 (4.17)	7 (2.50)		
Neutrophil infiltration, umbilical cord substance					0.09	0.02 (0.00–0.03)
Not seen	1130 (94.1)	7442 (92.8)	825 (90.5)	252 (90.0)		
Slight	34 (2.83)	265 (3.30)	36 (3.95)	13 (4.64)		
Moderate	0	5 (0.06)	1 (0.11)	0		
Marked	9 (0.75)	71 (0.89)	12 (1.32)	8 (2.86)		
Unknown/missing	28 (2.33)	239 (2.98)	38 (4.12)	7 (2.50)		
Fetal inflammation summary score	0 (0, 0)	0 (0, 0)	0 (0, 0)	0 (0, 0)	0.10	0.01 (-0.008 to 0.03)
<b>Membranes</b>						
Neutrophil infiltration, membrane roll, amnion					<b>0.002</b>	0.03 (0.01–0.04)
Not seen	1028 (85.6)	6736 (84.0)	732 (80.3)	223 (79.6)		
Slight	62 (5.16)	434 (5.41)	71 (7.79)	25 (8.93)		
Moderate	0	5 (0.06)	0	1 (0.36)		
Marked	16 (1.33)	158 (1.97)	24 (2.63)	9 (3.21)		
Unknown/missing	95 (7.91)	689 (8.59)	85 (9.32)	22 (7.86)		
Neutrophil infiltration, membrane roll, chorion					<b>0.006</b>	0.03 (0.009–0.04)
Not seen	1032 (85.9)	6718 (83.7)	742 (81.36)	216 (77.1)		
Slight	97 (8.08)	763 (9.51)	87 (9.54)	40 (14.3)		
Moderate	2 (0.17)	9 (0.11)	0	0		
Marked	39 (3.25)	288 (3.59)	45 (4.93)	18 (6.43)		
Unknown/missing	31 (2.58)	244 (3.04)	38 (4.17)	6 (2.14)		
Neutrophil infiltration, placental surface, amnion					0.06	0.03 (0.005–0.03)
Not seen	1011 (84.2)	6691 (83.4)	740 (81.1)	236 (84.3)		
Slight	44 (3.66)	290 (3.62)	45 (4.93)	13 (4.64)		
Moderate	1 (0.08)	2 (0.02)	1 (0.11)	1 (0.36)		
Marked	9 (0.75)	96 (1.20)	17 (1.86)	7 (2.50)		
Unknown/missing	136 (11.32)	943 (11.8)	109 (12.0)	23 (8.21)		
Neutrophil infiltration, placental surface, chorion					0.08	0.02 (0.00–0.03)
Not seen	1070 (89.1)	6983 (87.0)	766 (84.0)	239 (85.4)		
Slight	85 (7.08)	624 (7.78)	80 (8.77)	21 (7.50)		
Moderate	1 (0.08)	6 (0.07)	1 (0.11)	1 (0.36)		
Marked	19 (1.58)	186 (2.32)	29 (3.18)	13 (4.64)		
Unknown/missing	26 (2.16)	223 (2.78)	36 (3.95)	6 (2.14)		
Maternal inflammation summary score	0 (0, 0) <sup>A</sup>	0 (0, 0) <sup>A</sup>	0 (0, 0) <sup>A</sup>	0 (0, 1) <sup>A</sup>	<b>0.02</b>	0.008 (-0.01 to 0.03)

Decidua						
Decidual vessels, fibrinoid					0.21	0.02 (0.00–0.04)
Not seen	1106 (92.1)	7417 (92.5)	838 (91.9)	258 (92.1)		
Present	44 (3.66)	226 (2.82)	20 (2.19)	6 (2.14)		
Unable to determine/ unknown/missing	51 (4.25)	379 (4.72)	54 (5.92)	16 (5.71)		
Decidual vessels, atheroma					0.25	0.02 (0.00–0.04)
Not seen	1127 (93.8)	7533 (93.9)	844 (92.5)	260 (92.9)		
Present	21 (1.75)	83 (1.03)	10 (1.10)	3 (1.07)		
Unable to determine/ unknown/missing	53 (4.41)	406 (5.06)	58 (6.36)	17 (6.07)		
Syncytium, nuclear clumping					0.59	0.02 (0.00–0.02)
Normal	1046 (87.1)	6973 (86.9)	790 (86.6)	251 (89.6)		
Less than normal for term placenta	97 (8.08)	556 (6.93)	60 (6.58)	13 (4.64)		
Excessive for term placenta	29 (2.41)	238 (2.97)	21 (2.30)	9 (3.21)		
Excessive in parts	5 (0.41)	41 (0.51)	5 (0.55)	1 (0.36)		
Unable to determine/unknown/missing	24 (2.00)	214 (2.67)	36 (3.95)	6 (2.14)		
Maternal vascular malperfusion summary score	0 (0, 1)	0 (0, 1)	0 (0, 1)	0 (0, 1)	0.11	0.02 (-0.004 to 0.04)
Terminal villi						
Langhans' layer					0.39	0.02 (0.00–0.03)
Not seen	1173 (97.7)	7765 (96.8)	869 (95.3)	271 (96.8)		
Present	4 (0.33)	46 (0.57)	7 (0.77)	3 (1.07)		
Unknown/missing	24 (2.00)	211 (2.63)	36 (3.95)	6 (2.14)		
Hofbauer cells					0.91	0.007 (0.00–0.02)
Few	1155 (96.2)	7672 (95.6)	862 (94.5)	269 (96.1)		
Many	22 (1.83)	140 (1.75)	13 (1.43)	5 (1.79)		
Unknown/missing	24 (2.00)	210 (2.62)	37 (4.06)	6 (2.14)		
Stromal fibrosis					0.25	0.02 (0.00–0.04)
Not seen	1135 (94.5)	7499 (93.5)	851 (93.3)	261 (93.2)		
Present	41 (3.41)	313 (3.90)	25 (2.74)	13 (4.64)		
Unable to determine/unknown/missing	25 (2.08)	210 (2.62)	36 (3.95)	6 (2.14)		
Pathological edema					0.12	0.02 (0.00–0.04)
Not seen	1135 (94.5)	7553 (94.2)	847 (92.9)	271 (96.8)		
Present	42 (3.50)	258 (3.22)	29 (3.18)	3 (1.07)		
Unable to determine/unknown/missing	24 (2.00)	211 (2.63)	36 (3.95)	6 (2.14)		
Intervillous space						
Apparent maturity of placenta					0.72	0.01 (0.00–0.01)
Under 20 weeks	1 (0.08)	6 (0.07)	0	0		
20-27 weeks	4 (0.33)	19 (0.24)	1 (0.11)	0		
28-36 weeks	92 (7.66)	543 (6.77)	55 (6.03)	19 (6.79)		
37 weeks or over	1078 (89.8)	7237 (90.2)	820 (89.9)	255 (91.1)		
Unable to determine/unknown/missing	26 (2.16)	217 (2.71)	36 (3.95)	6 (2.14)		
Immaturity summary score	2 (2, 2)	2 (2, 2)	2 (2, 2)	2 (2, 2)	0.35	-0.01 (-0.03 to 0.007)

Data are median (IQR; Kruskal-Wallis/Wilcoxon test for non-parametric data with Steel-Dwass *post-hoc*) for continuous variables or n (%) (Likelihood Ratio Chi Square test) for categorical variables. \* $p < 0.05$ . Post hoc differences between groups are denoted by different letters. Effect sizes are Wilcoxon test effect size ( $r$ ) (95% CI) for continuous variables, or Cramer's  $V$  (95% CI) for categorical variables. UW = underweight. NW = normal weight. OW = overweight. OB = obese.

**Table 4.** Multivariable analyses for associations between maternal prepregnancy BMI (continuous) and microscopic placental pathologies in term pregnancies, N=10,415.

Placental pathology	Unadjusted model			Adjusted model		
	$\beta$ (95% CI)	OR (95% CI)	p-value	$\beta$ (95% CI)	OR (95% CI)	p-value
<b>Cord neutrophil infiltration</b>						
Umbilical vein Not seen Any degree of infiltration	0.02 (0.004–0.04)	1.02 (1.00–1.04)	*	0.03 (0.007–0.05)	1.03 (1.01–1.05)	**
Umbilical artery Not seen Any degree of infiltration	0.05 (0.02–0.08)	1.05 (1.02–1.08)	**	0.04 (0.003–0.07)	1.04 (1.00–1.07)	*
Umbilical cord substance Not seen Any degree of infiltration	0.04 (0.02–0.07)	1.04 (1.02–1.07)	***	0.04 (0.008–0.06)	1.04 (1.01–1.07)	**
Fetal inflammation score	0.01 (0.008–0.02)	-	****	0.01 (0.007–0.02)	-	****
<b>Membranes and neutrophil infiltration</b>						
Membrane roll, amnion Not seen Any degree of infiltration	0.06 (0.04–0.07)	1.06 (1.04–1.08)	****	0.05 (0.03–0.08)	1.06 (1.03–1.08)	****
Membrane roll, chorion Not seen Any degree of infiltration	0.05 (0.03–0.06)	1.05 (1.03–1.07)	****	0.04 (0.02–0.06)	1.04 (1.02–1.06)	****
Placental surface, amnion Not seen Any degree of infiltration	0.04 (0.01–0.06)	1.04 (1.01–1.06)	**	0.04 (0.01–0.06)	1.04 (1.01–1.07)	**
Placental surface, chorion Not seen Any degree of infiltration	0.04 (0.02–0.06)	1.04 (1.02–1.06)	****	0.04 (0.02–0.06)	1.04 (1.02–1.06)	***
Maternal inflammation score	0.03 (0.02–0.04)	-	****	0.03 (0.02–0.04)	-	****
<b>Decidua</b>						
Decidual vessels, fibrinoid Not seen Present	-0.03 (-0.07 to 0.01)	0.97 (0.94–1.01)	NS	-0.02 (-0.06 to 0.02)	0.98 (0.94–1.02)	NS
Decidual vessels, atheroma Not seen Present	-0.05 (-0.12 to 0.01)	0.95 (0.89–1.01)	NS	-0.06 (-0.13 to 0.004)	0.94 (0.88–1.00)	NS
Syncytium, nuclear clumping Normal/ < normal for term Excessive/in parts for term	0.002 (-0.03 to 0.03)	1.00 (0.97–1.03)	NS	0.001 (-0.03 to 0.04)	1.00 (0.97–1.04)	NS
Maternal vascular malperfusion	0.005 (0.002–0.008)	-	**	0.007 (0.004–0.01)	-	****
<b>Terminal villi</b>						
Langhans' layer Not seen Present	0.007 (-0.07 to 0.08)	1.01 (0.93–1.09)	NS	-0.008 (-0.09 to 0.07)	0.99 (0.92–1.07)	NS
Hofbauer cells Few Many	-0.03 (-0.08 to 0.02)	0.97 (0.92–1.02)	NS	-0.04 (-0.09 to 0.009)	0.96 (0.91–1.01)	NS

Stromal fibrosis	-0.006 (-0.04 to 0.03)	0.99 (0.96–1.03)	NS	0.002 (-0.03 to 0.04)	1.00 (0.97–1.04)	NS
Not seen						
Present						
Pathological edema	-0.03 (-0.07 to 0.004)	0.97 (0.93–1.00)	NS	-0.01 (-0.05 to 0.03)	0.99 (0.95–1.03)	NS
Not seen						
Present						
Intervillous space						
Apparent maturity of placenta	-0.02 (-0.05 to 0.003)	0.98 (0.96–1.00)	NS	-0.06 (-0.09 to -0.03)	0.94 (0.92–0.97)	****
Appropriate mature						
Immature						
Immaturity score	-0.0003 (-0.002 to 0.002)	-	NS	-0.0009 (-0.003 to 0.001)	-	NS

Data are  $\beta$  (95% CI) and unit odds ratios (95% CI) for presence of pathology from Logistic regression models with p-value from Likelihood Ratio Chi Square test for categorical variables, or  $\beta$  (95% CI) with p-value from Standard Least Squares models for continuous variables. The adjusted model includes fetal sex, maternal race, maternal age, smoking history, maternal education, socioeconomic status, gestational weight gain, and maternal diabetes mellitus status. NS (not significant):  $p > 0.05$ ; \* $p \leq 0.05$ ; \*\* $p \leq 0.01$ ; \*\*\* $p \leq 0.001$ ; \*\*\*\* $p \leq 0.0001$ .

**Table 5.** Associations between fetal sex and microscopic placental pathologies in preterm (N=1739) and term (N=10,415) pregnancies.

Placental pathology	Preterm				Term			
	Male (n=906)	Female (n=833)	p-value	Effect size	Male (n=5357)	Female (n=5058)	p-value	Effect size
<b>Cord</b>								
Neutrophil infiltration, umbilical vein			0.09	0.76 (0.56–1.04)			<b>0.0003</b>	1.26 (1.11–1.44)
Not seen	794 (87.6)	711 (85.4)			4599 (85.9)	4454 (88.1)		
Any degree of neutrophilic infiltration	81 (8.94)	95 (11.4)			594 (11.1)	455 (9.0)		
Unknown/missing	31 (3.42)	27 (3.24)			164 (3.06)	149 (2.95)		
Neutrophil infiltration, umbilical artery			0.09	0.72 (0.49–1.05)			0.17	1.18 (0.93–1.48)
Not seen	823 (90.8)	742 (89.1)			5027 (93.8)	4776 (94.4)		
Any degree of neutrophilic infiltration	51 (5.63)	64 (7.68)			166 (3.10)	134 (2.65)		
Unknown/missing	32 (3.53)	27 (3.24)			164 (3.06)	148 (2.93)		
Neutrophil infiltration, umbilical cord substance			0.07	0.71 (0.49–1.03)			<b>&lt;0.0001</b>	1.54 (1.27–1.86)
Not seen	823 (90.8)	739 (88.7)			4914 (91.7)	4735 (93.6)		
Any degree of neutrophilic infiltration	52 (5.74)	66 (7.92)			279 (5.21)	175 (3.46)		
Unknown/missing	31 (3.42)	28 (3.36)			164 (3.06)	148 (2.93)		
Fetal inflammation summary score	0 (0, 0)	0 (0, 0)	<b>0.04</b>	-0.05 (-0.10 to -0.004)	0 (0, 0)	0 (0, 0)	<b>0.0005</b>	0.03 (0.01–0.05)
<b>Membranes</b>								
Neutrophil infiltration, membrane roll, amnion			0.08	0.75 (0.54–1.04)			<b>0.0004</b>	1.30 (1.12–1.50)
Not seen	770 (85.0)	668 (80.2)			4459 (83.2)	4260 (84.2)		
Any degree of neutrophilic infiltration	74 (8.17)	86 (10.3)			464 (8.66)	341 (6.74)		
Unknown/missing	62 (6.84)	79 (9.48)			434 (8.10)	457 (9.04)		
Neutrophil infiltration, membrane roll, chorion			0.79	0.97 (0.76–1.23)			<b>0.0008</b>	1.21 (1.08–1.36)
Not seen	705 (77.8)	639 (76.7)			4424 (82.6)	4284 (84.7)		
Any degree of neutrophilic infiltration	173 (19.1)	162 (19.4)			772 (14.4)	616 (12.2)		
Unknown/missing	28 (3.09)	32 (3.84)			161 (3.01)	158 (3.12)		
Neutrophil infiltration, placental surface, amnion			0.22	0.80 (0.55–1.15)			<b>0.01</b>	1.26 (1.05–1.50)
Not seen	761 (84.0)	667 (80.1)			4460 (83.3)	4218 (83.4)		
Any degree of neutrophilic infiltration	60 (6.62)	66 (7.92)			300 (5.60)	226 (4.47)		
Unknown/missing	85 (9.38)	100 (12.0)			597 (11.1)	614 (12.1)		
Neutrophil infiltration, placental surface, chorion			0.87	1.02 (0.78–1.33)			<b>0.002</b>	1.22 (1.08–1.39)
Not seen	740 (81.7)	683 (82.0)			4612 (86.1)	4446 (87.9)		
Any degree of neutrophilic infiltration	134 (14.8)	121 (14.5)			596 (11.1)	470 (9.29)		
Unknown/missing	32 (3.53)	29 (3.48)			149 (2.78)	122 (2.81)		
Maternal inflammation summary score	0 (0, 1)	0 (0, 1)	0.28	-0.03 (-0.07 to 0.02)	0 (0, 0)	0 (0, 0)	<b>0.004</b>	0.03 (0.008–0.05)
<b>Decidua</b>								
Decidual vessels, fibrinoid			0.27	0.77 (0.48–1.23)			0.44	0.91 (0.72–1.15)
Not seen	818 (90.3)	740 (88.8)			4966 (92.7)	4653 (92.0)		
Present	34 (3.75)	40 (4.80)			146 (2.73)	150 (2.97)		
Unable to determine/unknown/missing	54 (5.96)	53 (6.36)			149 (2.78)	255 (5.04)		
Decidual vessels, atheroma			0.98	1.01 (0.43–2.39)			0.96	0.99 (0.69–1.43)
Not seen	837 (92.4)	769 (92.3)			5032 (93.9)	4732 (93.6)		
Present	11 (1.21)	10 (1.20)			60 (1.12)	57 (1.13)		
Unable to determine/unknown/missing	58 (6.40)	54 (6.48)			245 (4.57)	269 (5.32)		
Syncytium, nuclear clumping			<b>0.02</b>	0.53 (0.31–0.91)			0.94	1.01 (0.81–1.25)
Normal/Less than normal for term placenta	857 (94.6)	771 (92.6)			5028 (93.9)	4758 (94.1)		
Excessive for term placenta/ Excessive in parts	22 (2.43)	37 (4.44)			180 (3.36)	169 (3.34)		
Unable to determine/unknown/missing	27 (2.98)	25 (3.00)			149 (2.78)	131 (2.60)		

Maternal vascular malperfusion summary score	0 (0, 0)	0 (0, 0)	0.89	-0.003 (-0.05 to 0.05)	0 (0, 1)	0 (0, 1)	<b>&lt;0.0001</b>	0.04 (0.02–0.06)
<b>Terminal villi</b>								
Langhans' layer			0.47	0.82 (0.47–1.41)			0.76	1.08 (0.65–1.80)
Not seen	854 (94.3)	780 (93.6)			5178 (96.7)	4900 (96.9)		
Present	25 (2.76)	28 (3.36)			32 (0.60)	28 (0.55)		
Unknown/missing	27 (2.98)	25 (3.00)			147 (2.74)	130 (2.57)		
Hofbauer cells			0.23	1.26 (0.86–1.86)			0.94	0.99 (0.74–1.33)
Few	814 (89.8)	760 (91.2)			5119 (95.6)	4839 (95.7)		
Many	65 (7.17)	48 (5.76)			92 (1.72)	88 (1.74)		
Unknown/missing	27 (2.98)	25 (3.00)			146 (2.73)	131 (2.59)		
Stromal fibrosis			0.17	1.39 (0.87–2.21)			0.09	0.84 (0.69–1.03)
Not seen	832 (91.8)	777 (93.3)			5026 (93.8)	4720 (93.3)		
Present	46 (5.08)	31 (3.72)			185 (3.45)	207 (4.09)		
Unable to determine/unknown/missing	28 (3.09)	25 (3.00)			146 (2.73)	131 (2.59)		
Pathological edema			0.17	1.38 (0.87–2.20)			0.11	1.20 (0.96–1.49)
Not seen	833 (91.9)	776 (93.2)			5025 (93.8)	4781 (94.5)		
Present	46 (5.08)	31 (3.72)			185 (3.45)	147 (2.91)		
Unable to determine/unknown/missing	27 (2.98)	26 (3.12)			147 (2.74)	130 (2.57)		
<b>Intervillous space</b>								
Apparent maturity of placenta			0.27	-			0.17	-
Under 20 weeks	2 (0.22)	2 (0.24)			1 (0.02)	6 (0.12)		
20-27 weeks	21 (2.32)	31 (3.72)			14 (0.26)	10 (0.20)		
28-36 weeks	192 (21.2)	158 (19.0)			371 (6.93)	338 (6.68)		
37 weeks or over	663 (73.2)	613 (73.6)			4819 (90.0)	4571 (90.4)		
Unable to determine/unknown/missing	28 (3.09)	29 (3.48)			152 (2.84)	133 (2.63)		
Immaturity summary score	2 (2, 2)	2 (2, 2)	0.45	0.02 (-0.03 to 0.06)	2 (2, 2)	2 (2, 2)	0.23	0.01 (-0.008 to 0.03)

Data are median (IQR; Kruskal-Wallis/Wilcoxon test for non-parametric data with Steel-Dwass *post-hoc*) for continuous variables, or n (%) (Likelihood Ratio Chi Square test) for categorical variables. \*p<0.05. Effect sizes are Wilcoxon test effect size (r) (95% CI) for continuous variables, or odds ratios (95% CI) for presence of pathology in male placentae for categorical variables.

**Table 6.** Associations between fetal sex and macroscopic placental pathologies in preterm (N=1739) and term (N=10,415) pregnancies.

Placental pathology	Preterm				Term			
	Male (n=906)	Female (n=833)	p-value	Effect size	Male (n=5357)	Female (n=5058)	p-value	Effect size
<b>Placenta<sup>1</sup></b>								
Placenta shape			0.64	-			0.17	-
Non-partite	804 (88.7)	727 (87.3)			4839 (90.3)	4553 (90.0)		
Bipartite	4 (0.44)	1 (0.12)			65 (1.21)	68 (1.34)		
Tripartite	0	0			0	2 (0.04)		
Succenturiate	12 (1.32)	11 (1.32)			61 (1.14)	53 (1.05)		
Membranous placenta	0	0			0	2 (0.04)		
Crescent shaped	0	0			2 (0.04)	0		
Irregular shape	4 (0.44)	3 (0.36)			23 (0.43)	23 (0.45)		
Unknown/missing	82 (9.05)	91 (10.9)			518 (9.67)	357 (7.06)		
Weight	382 (320, 450)	375 (320, 435)	0.17	0.03 (-0.02 to 0.08)	425 (370, 485)	420 (370, 480)	0.06	0.02 (-0.002 to 0.04)
Largest diameter	18 (17, 19)	18 (17, 19)	0.61	0.01 (-0.04 to 0.06)	19 (18, 20)	19 (18, 20)	<b>0.03</b>	0.02 (0.002–0.04)
Smallest diameter	16 (14, 17)	15 (14, 17)	0.41	0.02 (-0.03 to 0.07)	16 (15, 18)	16 (15, 17)	0.19	0.01 (-0.006 to 0.03)
Thickness	20 (18, 24)	20 (18, 23)	0.38	0.02 (-0.02 to 0.07)	20 (20, 25)	20 (20, 25)	0.53	0.006 (-0.02 to 0.03)
Birthweight : placenta weight	7.34 (6.52, 8.32)	7.16 (6.36, 7.93)	<b>0.003</b>	0.07 (0.03–0.12)	7.56 (6.78, 8.38)	7.36 (6.65, 8.17)	<b>&lt;0.0001</b>	0.07 (0.05–0.09)
Birthweight : placental largest diameter	157 (140, 175)	150 (135, 166)	<b>&lt;0.0001</b>	0.13 (0.09–0.018)	169 (155, 184)	165 (151, 179)	<b>&lt;0.0001</b>	0.09 (0.07–0.11)
Birthweight : placental smallest diameter	183 (164, 202)	173 (156, 193)	<b>&lt;0.0001</b>	0.12 (0.08–0.17)	197 (179, 214)	191 (175, 208)	<b>&lt;0.0001</b>	0.09 (0.07–0.11)
Birthweight : placental thickness	140 (118, 162)	133 (116, 155)	<b>0.003</b>	0.07 (0.03–0.12)	147 (126, 170)	143 (125, 164)	<b>&lt;0.0001</b>	0.06 (0.04–0.08)
<b>Cord</b>								
Cord number of vessels			0.85	0.90 (0.29–2.79)			0.10	0.66 (0.40–1.09)
Two	821 (90.6)	736 (88.4)			4965 (92.7)	4659 (92.1)		
Three	6 (0.66)	6 (0.72)			26 (0.49)	37 (0.73)		
Other/unknown/missing	79 (8.72)	91 (10.9)			366 (6.83)	362 (7.16)		
Cord edema			0.97	1.01 (0.62–1.64)			<b>0.02</b>	1.46 (1.07–1.99)
Not seen	781 (86.2)	700 (84.0)			4817 (89.9)	4562 (90.2)		
Present	36 (3.97)	31 (3.72)			103 (1.92)	67 (1.32)		
Unknown/missing	89 (9.82)	101 (12.1)			437 (8.16)	429 (8.48)		
<b>Membranes and fetal surface</b>								
Opacity of membranes			0.97	1.01 (0.69–1.46)			0.45	1.06 (0.91–1.25)
Not opaque	763 (84.2)	684 (82.1)			4648 (86.8)	4384 (86.7)		
Any degree of opacity	64 (7.06)	57 (6.84)			347 (6.48)	308 (6.09)		
Unknown/missing	79 (8.72)	92 (11.0)			362 (6.76)	366 (7.24)		
Thrombosed fetal vessels			0.93	1.05 (0.35–3.13)			0.73	0.88 (0.42–1.82)
Not seen	821 (90.6)	738 (88.6)			4983 (93.0)	4687 (92.7)		
Present	7 (0.77)	6 (0.72)			14 (0.26)	15 (0.30)		
Unknown/missing	78 (8.61)	89 (10.7)			360 (6.72)	356 (7.04)		
<b>Cut surface</b>								
Infarct size			0.89	0.98 (0.77–1.26)			<b>&lt;0.0001</b>	1.22 (1.11–1.33)
Not applicable	660 (72.8)	593 (71.2)			3546 (66.2)	3513 (69.5)		
Any infarcts seen	164 (18.1)	150 (18.0)			1433 (26.8)	1167 (23.1)		
Unknown/missing	82 (9.05)	90 (10.8)			378 (7.06)	378 (7.47)		

Cut surface calcification			0.43	1.08 (0.89–1.32)			0.14	0.94 (0.87–1.02)
None	444 (49.0)	414 (49.7)			2051 (66.2)	1860 (36.8)		
Any calcification seen	380 (41.9)	327 (39.3)			2926 (54.6)	2819 (55.7)		
Unknown/missing	82 (9.05)	92 (11.0)			380 (7.09)	379 (7.49)		

Data are median (IQR; Kruskal-Wallis/Wilcoxon test for non-parametric data with Steel-Dwass *post-hoc*) for continuous variables, or n (%) (Likelihood Ratio Chi Square test) for categorical variables. \* $p < 0.05$ . Effect sizes are Wilcoxon test effect size ( $r$ ) (95% CI) for continuous variables, or odds ratios (95% CI) for presence of pathology in male placentae for categorical variables. <sup>1</sup>The top and bottom 0.5% of raw infant and placental anthropometry data (birthweight [g], placental weight [g], placental diameter [cm], and placental thickness [mm]) were excluded to remove biologically implausible data.



## Discussion

We evaluated the associations between maternal prepregnancy BMI and the prevalence of placental pathologies in preterm and term pregnancies, to better understand the placental mechanisms that may explain poor pregnancy and offspring outcomes in pregnancies complicated by suboptimal maternal BMI. Using data from 12,154 pregnancies from the Collaborative Perinatal Project, we found placental inflammation was increased in pregnancies complicated by maternal obesity, and notably, the inflammatory response was different based on gestational age. Maternal obesity also associated with increased MVM of the placenta, and increased maternal BMI associated with greater odds of having an appropriate mature placenta at term. Placental efficiency was highest in pregnancies where mothers were underweight and in male placentae, and pathologies also differed by fetal sex. Suboptimal maternal BMI thus alters normal gestational tissue development, with likely effects on function.

The inflammatory conditions established by maternal obesity may favour placental inflammation. In support of this, we found that higher maternal BMI associated with increased fetal (e.g. neutrophilic infiltration of the umbilical vein, artery, and cord substance) inflammation at preterm, and maternal (e.g. neutrophilic infiltration of the amnion and chorion membranes, amnion and chorion of the placenta, and opacity of membranes) gestational tissue inflammation at term. While few studies have characterised fetal- and maternal-specific placental inflammation in the context of both maternal BMI and gestational age, at term, maternal inflammation has been previously characterized in pregnancies with obesity, evidenced by increased pro-inflammatory cytokines in the placenta<sup>30</sup>, and increased maternal, but not fetal, inflammatory lesions<sup>17,56</sup>. Other studies have found no differences in placental inflammation by maternal BMI in term pregnancies, however, these cohorts had a small number of cases<sup>57,58</sup>. Less is known about the relationships between maternal obesity and specific placental inflammation at preterm, however, maternal obesity has been associated with greater risk of chorioamnionitis leading to preterm birth<sup>59</sup>, and a combination of maternal (defined as inflammation in the chorion, amnion, and decidua) and fetal (inflammation of the umbilical cord and chorionic plate fetal vessels) gestational tissue inflammation has been linked to higher risk of extreme preterm birth than maternal gestational tissue inflammation alone<sup>60</sup>. In the context of ascending infection, fetal placental inflammation of the umbilical cord has been associated with greater neonatal morbidity and mortality, particularly among preterm pregnancies, than maternal placental inflammation<sup>61-63</sup>. Our study, unlike many others, considers both suboptimal maternal BMI and gestational age, and suggests that increased maternal BMI associates with fetal placental inflammation at preterm, which has been linked to adverse pregnancy and offspring outcomes<sup>64,65</sup>, and maternal focused placental inflammation at term. Fetal inflammation of the placenta at preterm could thus be an important risk factor for adverse offspring outcomes, and maternal placental inflammation, though less frequently associated with clinical correlates<sup>64</sup>, nonetheless suggests that suboptimal maternal BMI alters gestational tissue histomorphology.

Interestingly, preterm female placentae had increased fetal inflammation, while term male placentae had increased fetal and maternal inflammation. Few studies have observed gestational age-specific sex differences in placental inflammation, and studies that have shown increased female gestational tissue inflammation often only consider term placentae. For example, female placentae have been shown to have increased chronic villitis in pregnancies complicated by maternal obesity,

however those observations were restricted to pregnancies at or near term<sup>15</sup>, as well as increased expression of genes related to immune regulation in normal, term pregnancies<sup>66</sup>. Sex-specific differences have also been observed in pregnancies exacerbated by other inflammatory conditions, where female placentae have increased mRNA expression levels of TNF- $\alpha$ , IL-1 $\beta$ , IL-6, IL-8, and IL-5 in pregnancies where mothers had asthma, compared to levels in male placentae<sup>67</sup>. Further, peripheral blood mononuclear cells treated with lipopolysaccharide from pregnant women carrying female fetuses had greater stimulated production of IL-6, TNF- $\alpha$ , and IL-1 $\beta$  compared to women carrying male fetuses, suggesting a greater response to immune challenge<sup>68</sup>. These findings may suggest that male and female fetuses implement different survival strategies in response to the same adverse environmental stimuli, where females may mount stronger responses, while males make minimal adaptations and continue to prioritize growth<sup>69,70</sup>. This may explain our finding of increased female fetal gestational tissue inflammation. Further, smaller body size<sup>71,72</sup> may allow female fetuses to gestate longer in the context of intrauterine inflammation, while continuing to mount an immune response to adverse environmental conditions, while larger male fetuses<sup>71,72</sup> may trigger uterine mechanical stretch, and in conjunction with inflammatory signals<sup>73,74</sup>, initiate earlier parturition.

In contrast, male placentae have been observed to have higher rates of chronic inflammatory lesions in extreme preterm pregnancies<sup>75</sup>, chronic deciduitis among extreme preterm pregnancies with pre-eclampsia and intrauterine growth restriction<sup>76</sup>, and enrichment in inflammatory pathways<sup>77</sup>. Our findings suggest that male placentae are more susceptible to inflammation in term pregnancies, which could increase risk for impaired growth or neurodevelopment and long term health outcomes<sup>78,79</sup>, while increased fetal inflammation among preterm female placentae warrants further investigation. Given the associations of maternal obesity and male sex with increased placental inflammation, term males born to mothers with obesity may be most susceptible to placental inflammation. To further investigate this, we conducted an exploratory analysis to assess whether fetal sex associated with placental inflammation among pregnancies with obesity alone. Increased odds of inflammation in male placentae at term only, though not to the same extent as BMI inclusive differences, suggests that both maternal obesity and male sex may be independent risk factors for placental inflammation at term. Further studies are needed to corroborate this finding.

We found MVM also associated with increased maternal BMI among term pregnancies, consistent with existing data<sup>80</sup>. Previous studies have documented increased maternal vascular lesions<sup>58</sup> and decidual vasculopathy, but no other lesions associated with MVM, in placentae from term pregnancies complicated by obesity compared to normal weight, although this was attributed to maternal hypertensive disease<sup>15</sup>. MVM lesions impair intervillous blood flow, altering oxygen and nutrient delivery to the fetus<sup>47</sup>, and are associated with adverse offspring outcomes, including preterm birth, intrauterine growth restriction, and small for gestational age infants<sup>47</sup>. Our findings suggest that the adverse environment established by maternal obesity may impair the development and function of placental vasculature, and thus fetal development. Despite known associations of MVM and preterm birth<sup>47,81</sup>, increased BMI associated with MVM only among term pregnancies in our cohort<sup>15,47,58</sup>, suggesting the importance of vascular pathologies across gestation in pregnancies complicated by maternal obesity. Further, male placentae had increased MVM lesions compared to females at term in our study, consistent with other findings of increased decidual vasculopathy in males<sup>15</sup>. Thus, placental vasculature pathology

may not be so severe as to result in early pregnancy or other adverse perinatal events, but may still have long term implications for the infant.

In contrast to previous studies, we found increased maternal BMI associated with greater odds of having an appropriately mature placenta at term. Placentae from women with obesity have been shown to have immaturity of the villous tree compared to women of normal weight<sup>57</sup>, suggesting structural and functional maladaptation of the vasculature or decreased efficiency in maternal-fetal exchange<sup>57</sup>. We did, however observe other placental vascular pathologies, evidenced by increased MVM with higher maternal BMI. Placental maturity was classified by CPP pathologists as placental appearance of <20, 20–27, 28–36, or ≥37 weeks' gestation, based on presence of fibrin under the chorionic plate, presence of cysts on the cut surfaces, lack of Langhans layer, relative uniformity of villous size, crowded fetal capillaries within villi, and increased frequency of syncytial knots. In addition to the lower number of cases of obesity in our cohort relative to the current rates, changes to criteria used to diagnose distal villous immaturity, which was only introduced after the time of the CPP<sup>82</sup>, may in part account for these differences in apparent placental maturity. Overall, a consistent, universal classification of placental maturation disorders would be beneficial in reducing variation in assessment of placental maturity across studies<sup>83</sup>.

Our findings of decreased placental size and increased infant birthweight to placental weight ratio with lower maternal BMI are consistent with reduced nutrient availability in underweight pregnancies<sup>5,20,84</sup>, and suggest that the placenta may adapt to increase nutrient delivery to the fetus, whereas placentae from higher BMI pregnancies may adapt by regulating nutrient transfer to the fetus in the face of sufficient or overabundance of nutrients<sup>85,86</sup>. Conversely, among term pregnancies, decreased birthweight to placental smallest diameter ratio with lower maternal BMI could suggest lower placental efficiency in pregnancies with underweight. However, placental diameter is reflective of the lateral growth of the placenta and area of the uterine lining that it encompasses, and may be influenced by inter-individual variations such as differences in placental shape, whereas placental weight captures multiple dimensions of placental growth<sup>87</sup>. Further, males had higher birthweight to placental size ratios in both preterm and term pregnancies, consistent with previous studies<sup>88</sup>, suggesting greater placental efficiency than females. Male fetuses tend to grow more rapidly than females and invest greater resources in growth than placental development and reserve capacity<sup>66,69-71</sup>, and as a result, may be more susceptible to placental insults as well as adverse later health outcomes<sup>71</sup>. Sex-based differences in fetoplacental growth and development may be attributed to a number of contributing biological factors, including X chromosome inactivation<sup>69,89</sup>, sex-specific response to glucocorticoids<sup>69,90</sup>, and levels of sex hormones<sup>69</sup>. Taken together, our results may suggest that males born to mothers who are underweight have the greatest placental efficiency, particularly at term.

Strengths of our study include the large population-based cohort, where previous studies have been limited to animal models of maternal malnutrition or inflammation to assess placental histopathology, or have lacked population size and comprehensive data. Importantly, the large sample size, collection of socioeconomic and demographic factors, deep phenotyping, and prospective nature of the dataset enables a thorough investigation of the relationships between maternal BMI and placental pathologies in a diverse population. To leverage the extensive data collected, future studies could further explore the role of demographic factors on placental pathology, such as socioeconomic status, in addition to suboptimal maternal BMI, given the independent risks associated with

both low socioeconomic status<sup>91</sup> and with maternal underweight and obesity<sup>15-17,19</sup> on outcomes such as preterm birth and placental pathology, respectively. Due to the cohort's historical nature, a limitation of our study is that the prevalence of obesity was lower than current rates; only 2.63% of our cohort were classified as having obesity prepregnancy, compared to 29% of American women currently<sup>92</sup>. Rates of smoking were also increased during the time of the study compared to rates today (42-45% during the time of CPP data collection<sup>93</sup> compared to 16% in 2019<sup>94</sup>), and no data were collected on maternal alcohol consumption<sup>95</sup>. Additionally, no data were provided for GDM specifically, which is associated with adverse pregnancy outcomes and is comorbid with obesity<sup>96,97</sup>, however, rates of GDM were much lower during the time of the study than current rates (0.3% in 1979<sup>98</sup> compared to 7.6% from 2007-2014<sup>99</sup>), so any confounding is likely to be minimal. Placental pathology was not re-assessed, however, definitions of pathologies were largely consistent between the CPP and current Amsterdam Placental Workshop Group Consensus Statement criteria<sup>18</sup>, particularly for our variables of interest. Given the population-based design, our findings may still be applicable to a broad and diverse population today, due to the large sample size and thorough collection of demographic and placental pathology data.

Given our findings of suboptimal maternal BMI, particularly high BMI, and risk of placental pathology, strategies to optimize maternal weight during pregnancy that align with improving patient-centred health outcomes and addressing root causes of obesity<sup>100</sup> should be investigated for their effects on placental development and function, including other pregnancy outcomes. To date, there is limited evidence that dietary and lifestyle interventions are effective in improving pregnancy outcomes for women who have high BMI, but may still have implications for weight management. For example, a diet and physical activity intervention improved maternal lipid metabolic profiles across pregnancy in women with obesity, but did not improve the primary study outcomes of interest, prevalence of maternal diabetes mellitus and large for gestational age infants at birth<sup>101</sup>. However, in addition to improved diet and physical activity, the trial did show beneficial changes in maternal gestational weight gain<sup>101</sup>, and similar improvements in gestational weight gain have been seen in other diet and physical activity studies among women who were overweight prepregnancy<sup>102</sup>. Nonetheless, it is possible that modest changes in maternal diet and activity may result in subtle, but important, improvements in placental development and function, measures not often considered in maternal lifestyle intervention studies. For example, maternal exercise in a high fat diet mouse model of maternal obesity has shown improvements in maternal weight gain, serum glucose and lipid levels, and insulin sensitivity, and protective effects on placental vascular factors, in addition to prevented fetal overgrowth<sup>103</sup>. This study contributes to better understanding the role of the placenta in pregnancies complicated by suboptimal maternal BMI, to ultimately help inform clinical and policy guidelines.

Our data demonstrate that compared to normal weight, maternal underweight and obesity prepregnancy, even in the absence of other significant pregnancy complications, are not inert conditions for the developing placenta<sup>16,37</sup>, which may have consequences not only for immediate pregnancy and fetal outcomes but postnatal growth and health trajectories<sup>38,39,44,104</sup>. Characterising placental (mal)adaptations to common maternal conditions using clinically-relevant indicators can help to understand the mechanisms through which these conditions affect the developing offspring, and aid clinical decision making to better support high-risk pregnancies and inform interventions to optimise pregnancy, placental, and infant health.

## Funding and Competing Interests

The authors have no competing interests to declare. This research is funded by the Faculty of Science, Carleton University. HS was supported by a Mitacs Research Training Award. KLC is supported by grants from the Canadian Institutes of Health Research, Natural Sciences and Engineering Research Council of Canada, the Molly Towell Perinatal Research Foundation (New Investigator), and Carleton University Office of Research.

## Acknowledgments

The authors thank the U.S. National Archives for the publicly available Collaborative Perinatal Project data, and Marina White for her assistance with obtaining the dataset.

## Author Contributions

Conceptualization, methodology: HS, KLC, DG, LNA; formal analysis: HS; writing—original draft preparation: HS, KLC; writing—review and editing: HS, KLC, DG, LNA; visualization: HS, KLC.

## References

1. Di Angelantonio E, Bhupathiraju SN, Wormser D, et al. Body-mass index and all-cause mortality: individual-participant-data meta-analysis of 239 prospective studies in four continents. *The Lancet*. 2016;388(10046):776-786. doi:10.1016/S0140-6736(16)30175-1
2. Black RE, Victora CG, Walker SP, et al. Maternal and child undernutrition and overweight in low-income and middle-income countries. *Lancet*. Aug 3 2013;382(9890):427-451. doi:10.1016/s0140-6736(13)60937-x
3. Gotay CC, Katzmarzyk PT, Janssen I, Dawson MY, Aminoltejeri K, Bartley NL. Updating the Canadian obesity maps: an epidemic in progress. *Can J Public Health*. Nov 8 2012;104(1):e64-8. doi:10.1007/bf03405657
4. Gaccioli F, Lager S, Powell TL, Jansson T. Placental transport in response to altered maternal nutrition. *J Dev Orig Health Dis*. Apr 2013;4(2):101-15. doi:10.1017/s2040174412000529
5. Yu Z, Han S, Zhu J, Sun X, Ji C, Guo X. Pre-Pregnancy Body Mass Index in Relation to Infant Birth Weight and Offspring Overweight/Obesity: A Systematic Review and Meta-Analysis. *PLOS ONE*. 2013;8(4):e61627. doi:10.1371/journal.pone.0061627
6. Basatemur E, Gardiner J, Williams C, Melhuish E, Barnes J, Sutcliffe A. Maternal prepregnancy BMI and child cognition: a longitudinal cohort study. *Pediatrics*. Jan 2013;131(1):56-63. doi:10.1542/peds.2012-0788
7. Cox B, Tsamou M, Vrijens K, et al. A Co-expression Analysis of the Placental Transcriptome in Association With Maternal Pre-pregnancy BMI and Newborn Birth Weight. *Front Genet*. 2019;10:354. doi:10.3389/fgene.2019.00354
8. Cotechini T, Hopman WJ, Graham CH. Inflammation-induced fetal growth restriction in rats is associated with altered placental morphometrics. *Placenta*. 2014/08/01/ 2014;35(8):575-581. doi:<https://doi.org/10.1016/j.placenta.2014.05.002>
9. Cotechini T, Graham CH. Aberrant maternal inflammation as a cause of pregnancy complications: A potential therapeutic target? *Placenta*. 2015/08/01/ 2015;36(8):960-966. doi:<https://doi.org/10.1016/j.placenta.2015.05.016>
10. Renaud SJ, Cotechini T, Quirt JS, Macdonald-Goodfellow SK, Othman M, Graham CH. Spontaneous Pregnancy Loss Mediated by Abnormal Maternal Inflammation in Rats Is Linked to Deficient Uteroplacental Perfusion. *The Journal of Immunology*. 2011;186(3):1799. doi:10.4049/jimmunol.1002679
11. Falcón BJ, Cotechini T, Macdonald-Goodfellow SK, Othman M, Graham CH. Abnormal inflammation leads to maternal coagulopathies associated with placental haemostatic alterations in a rat model of foetal loss. *Thromb Haemost*. Mar 2012;107(3):438-47. doi:10.1160/th11-09-0626
12. Altmäe S, Segura MT, Esteban FJ, et al. Maternal Pre-Pregnancy Obesity Is Associated with Altered Placental Transcriptome. *PLoS One*. 2017;12(1):e0169223. doi:10.1371/journal.pone.0169223
13. Connor KL, Kibschull M, Matysiak-Zablocki E, et al. Maternal malnutrition impacts placental morphology and transporter expression: an origin for poor offspring growth. *The Journal of Nutritional Biochemistry*. 2020/04/01/ 2020;78:108329. doi:<https://doi.org/10.1016/j.jnutbio.2019.108329>
14. Brett KE, Ferraro ZM, Yockell-Lelievre J, Gruslin A, Adamo KB. Maternal-fetal nutrient transport in pregnancy pathologies: the role of the placenta. *International journal of molecular sciences*. 2014;15(9):16153-16185. doi:10.3390/ijms150916153
15. Leon-Garcia SM, Roeder HA, Nelson KK, et al. Maternal obesity and sex-specific differences in placental pathology. *Placenta*. 2016/02/01/ 2016;38:33-40. doi:<https://doi.org/10.1016/j.placenta.2015.12.006>
16. Brouwers L, Franx A, Vogelvang TE, Houben ML, van Rijn BB, Nikkels PG. Association of Maternal Prepregnancy Body Mass Index With Placental Histopathological Characteristics in Uncomplicated Term Pregnancies. *Pediatr Dev Pathol*. Jan-Feb 2019;22(1):45-52. doi:10.1177/1093526618785838
17. Bar J, Schreiber L, Saruhanov E, Ben-Haroush A, Golan A, Kovo M. Placental histopathological findings in obese and nonobese women with complicated and uncomplicated pregnancies. *Arch Gynecol Obstet*. Dec 2012;286(6):1343-7. doi:10.1007/s00404-012-2450-z
18. Khong TY, Mooney EE, Arieli I, et al. Sampling and Definitions of Placental Lesions: Amsterdam Placental Workshop Group Consensus Statement. *Archives of Pathology & Laboratory Medicine*. 2016;140(7):698-713. doi:10.5858/arpa.2015-0225-CC
19. Schulz LC, Schlitt JM, Caesar G, Pennington KA. Leptin and the Placental Response to Maternal Food Restriction During Early Pregnancy in Mice1. *Biology of Reproduction*. 2012;87(5)doi:10.1095/biolreprod.112.103218
20. Belkacemi L, Nelson DM, Desai M, Ross MG. Maternal Undernutrition Influences Placental-Fetal Development1. *Biology of Reproduction*. 2010;83(3):325-331. doi:10.1095/biolreprod.110.084517
21. Dimasuy KG, Boeuf P, Powell TL, Jansson T. Placental Responses to Changes in the Maternal Environment Determine Fetal Growth. 10.3389/fphys.2016.00012. *Frontiers in Physiology*. 2016;7:12.
22. Myatt L, Maloyan A. Obesity and Placental Function. *Semin Reprod Med*. // 27.01.2016 2016;34(01):042-049. doi:10.1055/s-0035-1570027
23. Díaz P, Powell TL, Jansson T. The role of placental nutrient sensing in maternal-fetal resource allocation. *Biology of reproduction*. 2014;91(4):82-82. doi:10.1095/biolreprod.114.121798
24. Akhaphong B, Baumann DC, Beetch M, et al. Placental mTOR complex 1 regulates fetal programming of obesity and insulin resistance in mice. *JCI Insight*. 07/08/ 2021;6(13)doi:10.1172/jci.insight.149271
25. Howell KR, Powell TL. Effects of maternal obesity on placental function and fetal development. *Reproduction*. 01 Mar. 2017 2017;153(3):R97-R108. doi:10.1530/REP-16-0495
26. Jansson N, Rosario FJ, Gaccioli F, et al. Activation of placental mTOR signaling and amino acid transporters in obese women giving birth to large babies. *The Journal of clinical endocrinology and metabolism*. 2013;98(1):105-113. doi:10.1210/jc.2012.2667
27. Han Z, Mulla S, Beyene J, Liao G, McDonald SD. Maternal underweight and the risk of preterm birth and low birth weight: a systematic review and meta-analyses. *Int J Epidemiol*. Feb 2011;40(1):65-101. doi:10.1093/ije/dyq195
28. Roos S, Jansson N, Palmberg I, Säljö K, Powell TL, Jansson T. Mammalian target of rapamycin in the human placenta regulates leucine transport and is down-regulated in restricted fetal growth. *J Physiol*. Jul 1 2007;582(Pt 1):449-59. doi:10.1113/jphysiol.2007.129676
29. Lager S, Powell TL. Regulation of Nutrient Transport across the Placenta. *Journal of Pregnancy*. 2012/12/10 2012;2012:179827. doi:10.1155/2012/179827
30. Roberts KA, Riley SC, Reynolds RM, et al. Placental structure and inflammation in pregnancies associated with obesity. *Placenta*. 2011/03/01/ 2011;32(3):247-254. doi:<https://doi.org/10.1016/j.placenta.2010.12.023>

31. Challier JC, Basu S, Bintein T, et al. Obesity in pregnancy stimulates macrophage accumulation and inflammation in the placenta. *Placenta*. 2008;29(3):274-281. doi:10.1016/j.placenta.2007.12.010
32. Yang X, Li M, Haghiaci M, Catalano PM, O'Tierney-Ginn P, Hauguel-de Mouzon S. Causal relationship between obesity-related traits and TLR4-driven responses at the maternal-fetal interface. *Diabetologia*. 2016;59(11):2459-2466. doi:10.1007/s00125-016-4073-6
33. Aye IL, Lager S, Ramirez VI, et al. Increasing maternal body mass index is associated with systemic inflammation in the mother and the activation of distinct placental inflammatory pathways. *Biol Reprod*. Jun 2014;90(6):129. doi:10.1095/biolreprod.113.116186
34. Zhu MJ, Du M, Nathanielsz PW, Ford SP. Maternal obesity up-regulates inflammatory signaling pathways and enhances cytokine expression in the mid-gestation sheep placenta. *Placenta*. 2010/05/01/2010;31(5):387-391. doi:<https://doi.org/10.1016/j.placenta.2010.02.002>
35. Buddeberg BS, Sharma R, O'Driscoll JM, Kaelin Agten A, Khalil A, Thilaganathan B. Cardiac maladaptation in obese pregnant women at term. <https://doi.org/10.1002/uog.20170>. *Ultrasound in Obstetrics & Gynecology*. 2019/09/01 2019;54(3):344-349. doi:<https://doi.org/10.1002/uog.20170>
36. Sarno L, Maruotti GM, Saccone G, Morlando M, Sirico A, Martinelli P. Maternal body mass index influences umbilical artery Doppler velocimetry in physiologic pregnancies. <https://doi.org/10.1002/pd.4499>. *Prenatal Diagnosis*. 2015/02/01 2015;35(2):125-128. doi:<https://doi.org/10.1002/pd.4499>
37. Romero R, Kim YM, Pacora P, et al. The frequency and type of placental histologic lesions in term pregnancies with normal outcome. *Journal of perinatal medicine*. 2018;46(6):613-630. doi:10.1515/jpm-2018-0055
38. Barker DJ, Thornburg KL, Osmond C, Kajantie E, Eriksson JG. The surface area of the placenta and hypertension in the offspring in later life. *Int J Dev Biol*. 2010;54(2-3):525-30. doi:10.1387/ijdb.082760db
39. Godfrey KM. The Role of the Placenta in Fetal Programming—A Review. *Placenta*. 2002/04/01/ 2002;23:S20-S27. doi:<https://doi.org/10.1053/plac.2002.0773>
40. Catalog NA. Collaborative Perinatal Project Files. 2020. <https://catalog.archives.gov/id/606622>
41. Seaton SE, King S, Manktelow BN, Draper ES, Field DJ. Babies born at the threshold of viability: changes in survival and workload over 20 years. *Archives of disease in childhood Fetal and neonatal edition*. 2013;98(1):F15-F20. doi:10.1136/fetalneonatal-2011-301572
42. Gal H, Lysenko M, Stroganov S, et al. Molecular pathways of senescence regulate placental structure and function. *The EMBO journal*. 2019;38(18):e100849-e100849. doi:10.15252/embj.2018100849
43. Galal M, Symonds I, Murray H, Petraglia F, Smith R. Postterm pregnancy. *Facts, views & vision in ObGyn*. 2012;4(3):175-187.
44. Baptiste-Roberts K, Salafia CM, Nicholson WK, Duggan A, Wang NY, Brancati FL. Gross placental measures and childhood growth. *J Matern Fetal Neonatal Med*. Jan 2009;22(1):13-23. doi:10.1080/14767050802415728
45. Xu Y, Ren L, Zhai S, et al. Association Between Isolated Single Umbilical Artery and Perinatal Outcomes: A Meta-Analysis. *Med Sci Monit*. Apr 30 2016;22:1451-9. doi:10.12659/msm.897324
46. Redline RW, Ravishankar S. Fetal vascular malperfusion, an update. *APMIS*. 2018/07/01 2018;126(7):561-569. doi:10.1111/apm.12849
47. Ernst LM. Maternal vascular malperfusion of the placental bed. *APMIS*. 2018/07/01 2018;126(7):551-560. doi:10.1111/apm.12833
48. Nakayama M. Significance of pathological examination of the placenta, with a focus on intrauterine infection and fetal growth restriction. *Journal of Obstetrics and Gynaecology Research*. 2017/10/01 2017;43(10):1522-1535. doi:10.1111/jog.13430
49. Wallingford MC, Benson C, Chavkin NW, Chin MT, Frasch MG. Placental Vascular Calcification and Cardiovascular Health: It Is Time to Determine How Much of Maternal and Offspring Health Is Written in Stone. *Front Physiol*. 2018;9:1044. doi:10.3389/fphys.2018.01044
50. Loukeris K, Sela R, Baergen RN. Syncytial knots as a reflection of placental maturity: reference values for 20 to 40 weeks' gestational age. *Pediatr Dev Pathol*. Jul-Aug 2010;13(4):305-9. doi:10.2350/09-08-0692-0a.1
51. Christians J, Gynspan D. Placental villous hypermaturation is associated with improved neonatal outcomes. *Placenta*. 01/15 2019;76doi:10.1016/j.placenta.2019.01.012
52. Tang Z, Abrahams V, Mor G, Guller S. Placental Hofbauer cells and complications of pregnancy. *Annals of the New York Academy of Sciences*. 03/01 2011;1221:103-8. doi:10.1111/j.1749-6632.2010.05932.x
53. Myrianthopoulos NC, French KS. An application of the U.S. Bureau of the Census socioeconomic index to a large, diversified patient population. *Soc Sci Med*. Sep 1968;2(3):283-99. doi:10.1016/0037-7856(68)90004-8
54. Institute of Medicine and National Research Council Committee to Reexamine IOMPWG. The National Academies Collection: Reports funded by National Institutes of Health. In: Rasmussen KM, Yaktine AL, eds. *Weight Gain During Pregnancy: Reexamining the Guidelines*. National Academies Press (US) Copyright © 2009, National Academy of Sciences.; 2009.
55. Stanek J. Comparison of placental pathology in preterm, late-preterm, near-term, and term births. *American Journal of Obstetrics & Gynecology*. 2014;210(3):234.e1-234.e6. doi:10.1016/j.ajog.2013.10.015
56. He M, Curran P, Raker C, Martin S, Larson L, Bourjeily G. Placental findings associated with maternal obesity at early pregnancy. *Pathology - Research and Practice*. 2016/04/01/ 2016;212(4):282-287. doi:<https://doi.org/10.1016/j.prp.2016.01.006>
57. Loardi C, Falchetti M, Prefumo F, Facchetti F, Frusca T. Placental morphology in pregnancies associated with pregravid obesity. *J Matern Fetal Neonatal Med*. 2016;29(16):2611-6. doi:10.3109/14767058.2015.1094792
58. Kovo M, Zion-Saukhanov E, Schreiber L, et al. The Effect of Maternal Obesity on Pregnancy Outcome in Correlation With Placental Pathology. *Reprod Sci*. Dec 2015;22(12):1643-8. doi:10.1177/1933719115592712
59. Hadley EE, Discacciati A, Costantine MM, et al. Maternal obesity is associated with chorioamnionitis and earlier indicated preterm delivery among expectantly managed women with preterm premature rupture of membranes. *The Journal of Maternal-Fetal & Neonatal Medicine*. 2019/01/17 2019;32(2):271-278. doi:10.1080/14767058.2017.1378329
60. Gupta M, Mestan KK, Martin CR, et al. Impact of clinical and histologic correlates of maternal and fetal inflammatory response on gestational age in preterm births. *The Journal of Maternal-Fetal & Neonatal Medicine*. 2007/01/01 2007;20(1):39-46. doi:10.1080/14767050601156861
61. Katzman PJ, Metlay LA. Fetal Inflammatory Response is Often Present at Early Stages of Intra-amniotic Infection, and its Distribution along Cord is Variable. *Pediatric and Developmental Pathology*. 2010/07/01 2010;13(4):265-272. doi:10.2350/09-02-0604-OA.1
62. Kim CJ, Yoon BH, Romero R, et al. Umbilical arteritis and phlebitis mark different stages of the fetal inflammatory response. *American Journal of Obstetrics and Gynecology*. 2001/08/01/ 2001;185(2):496-500. doi:<https://doi.org/10.1067/mob.2001.116689>
63. Rogers BB, Alexander JM, Head J, McIntire D, Leveno KJ. Umbilical vein interleukin-6 levels correlate with the severity of placental inflammation and gestational age. *Human Pathology*. 2002/03/01/ 2002;33(3):335-340. doi:<https://doi.org/10.1053/hupa.2002.32214>
64. Lau J, Magee F, Qiu Z, Houbé J, Von Dadelszen P, Lee SK. Chorioamnionitis with a fetal inflammatory response is associated with higher neonatal mortality, morbidity, and resource use than chorioamnionitis displaying a maternal inflammatory response only. *American Journal of Obstetrics and Gynecology*. 2005/09/01/ 2005;193(3):708-713. doi:<https://doi.org/10.1016/j.ajog.2005.01.017>
65. Tang Q, Zhang L, Li H, Shao Y. The fetal inflammation response syndrome and adverse neonatal outcomes: a meta-analysis. *The Journal of Maternal-Fetal & Neonatal Medicine*. 2019:1-13. doi:10.1080/14767058.2019.1702942
66. Sood R, Zehnder JL, Druzina ML, Brown PO. Gene expression patterns in human placenta. *Proceedings of the National Academy of Sciences*. 2006;103(14):5478. doi:10.1073/pnas.0508035103
67. Scott NM, Hodyl NA, Murphy VE, et al. Placental Cytokine Expression Covaries with Maternal Asthma Severity and Fetal Sex. *The Journal of Immunology*. 2009;182(3):1411. doi:10.4049/jimmunol.182.3.1411

68. Mitchell AM, Palettas M, Christian LM. Fetal sex is associated with maternal stimulated cytokine production, but not serum cytokine levels, in human pregnancy. *Brain, behavior, and immunity*. 2017;60:32-37. doi:10.1016/j.bbi.2016.06.015
69. Clifton VL. Review: Sex and the human placenta: mediating differential strategies of fetal growth and survival. *Placenta*. Mar 2010;31 Suppl:S33-9. doi:10.1016/j.placenta.2009.11.010
70. Meakin AS, Cuffe JSM, Darby JRT, Morrison JL, Clifton VL. Let's Talk about Placental Sex, Baby: Understanding Mechanisms That Drive Female- and Male-Specific Fetal Growth and Developmental Outcomes. *International Journal of Molecular Sciences*. 2021;22(12)doi:10.3390/ijms22126386
71. Eriksson JG, Kajantie E, Osmond C, Thornburg K, Barker DJP. Boys live dangerously in the womb. *American journal of human biology : the official journal of the Human Biology Council*. May-Jun 2010;22(3):330-335. doi:10.1002/ajhb.20995
72. Galjaard S, Ameye L, Lees CC, et al. Sex differences in fetal growth and immediate birth outcomes in a low-risk Caucasian population. *Biology of Sex Differences*. 2019/09/09 2019;10(1):48. doi:10.1186/s13293-019-0261-7
73. Mendelson CR, Gao L, Montalbano AP. Multifactorial Regulation of Myometrial Contractility During Pregnancy and Parturition. Review. *Frontiers in Endocrinology*. 2019;10
74. Shynlova O, Tsui P, Dorogin A, Lye SJ. Monocyte Chemoattractant Protein-1 (CCL-2) Integrates Mechanical and Endocrine Signals That Mediate Term and Preterm Labor. *The Journal of Immunology*. 2008;181(2):1470. doi:10.4049/jimmunol.181.2.1470
75. Ghidini A, Salafia CM. Gender differences of placental dysfunction in severe prematurity. *BJOG: An International Journal of Obstetrics & Gynaecology*. 2005;112(2):140-144. doi:10.1111/j.1471-0528.2004.00308.x
76. Walker MG, Fitzgerald B, Keating S, Ray JG, Windrim R, Kingdom JCP. Sex-specific basis of severe placental dysfunction leading to extreme preterm delivery. *Placenta*. 2012/07/01/ 2012;33(7):568-571. doi:<https://doi.org/10.1016/j.placenta.2012.03.011>
77. Cvitic S, Longtine MS, Hackl H, et al. The human placental sexome differs between trophoblast epithelium and villous vessel endothelium. *PLoS one*. 2013;8(10):e79233-e79233. doi:10.1371/journal.pone.0079233
78. Al-Haddad BJS, Oler E, Armistead B, et al. The fetal origins of mental illness. *American Journal of Obstetrics and Gynecology*. 2019/12/01/ 2019;221(6):549-562. doi:<https://doi.org/10.1016/j.ajog.2019.06.013>
79. Romero R, Espinoza J, Gonçalves LF, Kusanovic JP, Friel LA, Nien JK. Inflammation in preterm and term labour and delivery. *Semin Fetal Neonatal Med*. Oct 2006;11(5):317-26. doi:10.1016/j.siny.2006.05.001
80. Huang L, Liu J, Feng L, Chen Y, Zhang J, Wang W. Maternal prepregnancy obesity is associated with higher risk of placental pathological lesions. *Placenta*. 2014/08/01/ 2014;35(8):563-569. doi:<https://doi.org/10.1016/j.placenta.2014.05.006>
81. Scifres CM, Parks WT, Feghali M, Caritis SN, Catov JM. Placental maternal vascular malperfusion and adverse pregnancy outcomes in gestational diabetes mellitus. *Placenta*. 2017/01/01/ 2017;49:10-15. doi:<https://doi.org/10.1016/j.placenta.2016.11.004>
82. Redline RW. Distal villous immaturity. *Diagnostic Histopathology*. 2012/05/01/ 2012;18(5):189-194. doi:<https://doi.org/10.1016/j.mpdhp.2012.02.002>
83. Turowski G, Vogel M. Re-view and view on maturation disorders in the placenta. <https://doi.org/10.1111/apm.12858>. *APMIS*. 2018/07/01 2018;126(7):602-612. doi:<https://doi.org/10.1111/apm.12858>
84. Liu L, Ma Y, Wang N, Lin W, Liu Y, Wen D. Maternal body mass index and risk of neonatal adverse outcomes in China: a systematic review and meta-analysis. *BMC Pregnancy and Childbirth*. 2019/03/29 2019;19(1):105. doi:10.1186/s12884-019-2249-z
85. Noguez P, Dos Santos E, Couturier-Tarrade A, et al. Maternal Obesity Influences Placental Nutrient Transport, Inflammatory Status, and Morphology in Human Term Placenta. *The Journal of Clinical Endocrinology & Metabolism*. 2020;doi:10.1210/clinem/dgaa660
86. Wallace JM, Horgan GW, Bhattacharya S. Placental weight and efficiency in relation to maternal body mass index and the risk of pregnancy complications in women delivering singleton babies. *Placenta*. 2012/08/01/ 2012;33(8):611-618. doi:<https://doi.org/10.1016/j.placenta.2012.05.006>
87. Salafia CM, Maas E, Thorp JM, Eucker B, Pezzullo JC, Savitz DA. Measures of Placental Growth in Relation to Birth Weight and Gestational Age. *American Journal of Epidemiology*. 2005;162(10):991-998. doi:10.1093/aje/kwi305
88. Wallace JM, Bhattacharya S, Horgan GW. Gestational age, gender and parity specific centile charts for placental weight for singleton deliveries in Aberdeen, UK. *Placenta*. 2013/03/01/ 2013;34(3):269-274. doi:<https://doi.org/10.1016/j.placenta.2012.12.007>
89. Reik W, Lewis A. Co-evolution of X-chromosome inactivation and imprinting in mammals. *Nature Reviews Genetics*. 2005/05/01 2005;6(5):403-410. doi:10.1038/nrg1602
90. Clifton VL, Murphy VE. Maternal asthma as a model for examining fetal sex-specific effects on maternal physiology and placental mechanisms that regulate human fetal growth. *Placenta*. 2004:S45-52.
91. Parker JD, Schoendorf KC, Kiely JL. Associations between measures of socioeconomic status and low birth weight, small for gestational age, and premature delivery in the United States. *Ann Epidemiol*. Jul 1994;4(4):271-8. doi:10.1016/1047-2797(94)90082-5
92. Driscoll A, Gregory E. Increases in Prepregnancy Obesity: United States, 2016–2019. <https://www.cdc.gov/nchs/products/databriefs/db392.htm>
93. (US) OoSaH. Chapter 2. Patterns of Tobacco Use Among Women and Girls. Text. 2001/03 2001;doi:<https://www.ncbi.nlm.nih.gov/books/NBK44311/>
94. Cornelius M, Wang T, Jamal A, Loretan C, Neff L. Tobacco Product Use Among Adults — United States, 2019. [https://www.cdc.gov/mmwr/volumes/69/wr/mm6946a4.htm?s\\_cid=mm69\\_46a4\\_w](https://www.cdc.gov/mmwr/volumes/69/wr/mm6946a4.htm?s_cid=mm69_46a4_w)
95. Klebanoff MA. The Collaborative Perinatal Project: a 50-year retrospective. *Paediatric and perinatal epidemiology*. 2009;23(1):2-8. doi:10.1111/j.1365-3016.2008.00984.x
96. Al-Goblan AS, Al-Alfi MA, Khan MZ. Mechanism linking diabetes mellitus and obesity. *Diabetes, metabolic syndrome and obesity : targets and therapy*. 2014;7:587-591. doi:10.2147/DMSO.S67400
97. Huynh J, Dawson D, Roberts D, Bentley-Lewis R. A systematic review of placental pathology in maternal diabetes mellitus. *Placenta*. 2015;36(2):101-114. doi:10.1016/j.placenta.2014.11.021
98. Lavery JA, Friedman AM, Keyes KM, Wright JD, Ananth CV. Gestational diabetes in the United States: temporal changes in prevalence rates between 1979 and 2010. <https://doi.org/10.1111/1471-0528.14236>. *BJOG: An International Journal of Obstetrics & Gynaecology*. 2017/04/01 2017;124(5):804-813. doi:<https://doi.org/10.1111/1471-0528.14236>
99. Casagrande SS, Linder B, Cowie CC. Prevalence of gestational diabetes and subsequent Type 2 diabetes among U.S. women. *Diabetes Res Clin Pract*. Jul 2018;141:200-208. doi:10.1016/j.diabres.2018.05.010
100. Wharton S, Lau DCW, Vallis M, et al. Obesity in adults: a clinical practice guideline. *Canadian Medical Association Journal*. 2020;192(31):E875. doi:10.1503/cmaj.191707
101. Mills HL, Patel N, White SL, et al. The effect of a lifestyle intervention in obese pregnant women on gestational metabolic profiles: findings from the UK Pregnancies Better Eating and Activity Trial (UPBEAT) randomised controlled trial. *BMC Medicine*. 2019/01/21 2019;17(1):15. doi:10.1186/s12916-018-1248-7
102. Hajian S, Aslani A, Sarbakhsh P, Fathnezhad-Kazemi A. The effectiveness of healthy lifestyle interventions on weight gain in overweight pregnant women: A cluster-randomized controlled trial. <https://doi.org/10.1002/nop2.577>. *Nursing Open*. 2020/11/01 2020;7(6):1876-1886. doi:<https://doi.org/10.1002/nop2.577>
103. Son JS, Liu X, Tian Q, et al. Exercise prevents the adverse effects of maternal obesity on placental vascularization and fetal growth. *J Physiol*. 2019;597(13):3333-3347. doi:10.1113/JP277698
104. Marciniak A, Patro-Malysza J, Kimber-Trojnar Ż, Marciniak B, Oleszczuk J, Leszczyńska-Gorzela B. Fetal programming of the metabolic syndrome. *Taiwanese Journal of Obstetrics and Gynecology*. 2017/04/01/ 2017;56(2):133-138. doi:<https://doi.org/10.1016/j.tjog.2017.01.001>

## Supplementary tables

**Supplementary Table 1.** Binary categories for placental pathology variables for multivariable analysis.

<b>Categorical variable</b>	<b>Collapsed binary categories</b>
Cord number of vessels	Three vessels vs two vessels
Cord edema (derived from “cord description” variable)	Presence of cord edema vs absence of cord edema
Opacity of membranes	Not opaque vs any degree of opacity (partially opaque, opaque)
Thrombosed fetal vessel	Not seen vs present
Placental infarcts (derived from “infarcts size” variable)	No infarcts seen (not applicable) vs any infarcts seen (all infarcts less than three centimetres, at least one infarct measures three or more centimetres)
Cut surface calcification	Not seen (none) vs any calcification seen (maternal surface only, calcification throughout)
Neutrophilic infiltration	Not seen vs any degree of neutrophilic infiltration seen (slight, moderate, or marked)
Decidual vessels fibrinoid	Not seen vs present
Decidual vessels atheroma	Not seen vs present
Langhan’s layer	Not seen vs present
Syncytium nuclear clumping	Normal/less than normal for term placenta vs excessive for term placenta/excessive in parts
Hofbauer cells	Few vs many
Stromal fibrosis	Not seen vs present (present- not qualified further, present- rare, present- many)
Pathological edema	Not seen vs present (present- not qualified further, present- rare, present- many)
Apparent maturity of the placenta	Preterm pregnancies: appropriate mature ( $\leq 36$ weeks) vs hyper-mature ( $\geq 37$ weeks) Term pregnancies: appropriate mature ( $\geq 37$ weeks) vs immature ( $\leq 36$ weeks)

**Supplementary Table 2.** Derived summary scores variable coding.

<b>Summary score</b>	<b>Variable coding</b>
Maternal inflammation summary score	Opacity of membranes: non-opaque membranes coded as zero, partially opaque as one, and opaque as two Neutrophilic infiltration of the amnion membrane, chorion membrane, amnion of the placenta, and chorion of the placenta: no neutrophilic infiltration coded as zero, slight infiltration coded as one, moderate coded as two, and marked coded as three
Fetal inflammation summary score	Neutrophilic infiltration of the umbilical vein, artery, and cord substance: no neutrophilic infiltration coded as zero, slight infiltration coded as one, moderate coded as two, and marked coded as three
Maternal vascular malperfusion (MVM) summary score	Presence of infarcts: any infarcts seen coded as one Syncytium-nuclear clumping: excessive syncytium-nuclear clumping coded as one
Immaturity summary score	Langhans' layer: presence of Langhans' layer coded as one Hofbauer cells: many Hofbauer cells coded as one Stromal fibrosis: no stromal fibrosis coded as one Syncytium-nuclear clumping: normal or less than normal syncytium-nuclear clumping coded as one

**Supplementary Table 3.** Maternal characteristics by prepregnancy BMI in preterm pregnancies, N=1739.

	Pregpregnancy BMI				p-value	Effect size
	UW (n=259)	NW (n=1287)	OW (n=155)	OB (n=38)		
<b>Maternal characteristics</b>						
Prepregnancy BMI	17.8 (17.0, 18.2) <sup>A</sup>	20.9 (19.8, 22.3) <sup>B</sup>	26.4 (25.5, 27.5) <sup>C</sup>	31.9 (30.2, 34.9) <sup>D</sup>	<0.0001	0.65 (0.62–0.67)
Gestational weight gain max (lbs)	23 (16, 28) <sup>A</sup>	19 (13, 26) <sup>B</sup>	19.5 (11, 28.8) <sup>AB</sup>	17 (7.5, 30) <sup>AB</sup>	0.005	-0.09 (-0.14 to -0.04)
Gestational weight gain <sup>1</sup> (n [%])					<0.0001	0.23 (0.19–0.26)
Inadequate	180 (69.5)	884 (68.7)	56 (36.1)	14 (36.8)		
Adequate	67 (25.9)	306 (23.8)	49 (31.6)	9 (23.7)		
Excessive	5 (1.93)	84 (6.53)	49 (31.6)	14 (36.8)		
Unknown/missing	7 (2.70)	13 (1.01)	1 (0.65)	1 (2.63)		
Diabetes mellitus <sup>2</sup> (n [%])					0.63	0.03 (0.00–0.06)
Yes	4 (1.54)	24 (1.86)	1 (0.65)	1 (2.63)		
No	253 (97.7)	1258 (97.7)	153 (98.7)	37 (97.4)		
Other/unknown/missing	2 (0.77)	5 (0.39)	1 (0.65)	0		
Maternal age (years)	18 (16, 20) <sup>A</sup>	18 (16, 20) <sup>A</sup>	19 (17, 22) <sup>B</sup>	22.5 (19, 26) <sup>C</sup>	<0.0001	0.04 (-0.01 to 0.09)
Maternal age grouped (years) (n [%])					<0.0001	0.13 (0.09–0.15)
≤19	177 (68.3)	881 (68.5)	83 (53.5)	15 (39.5)		
20-24	70 (27.0)	329 (25.6)	49 (31.6)	12 (31.6)		
25-29	9 (3.47)	57 (4.43)	18 (11.6)	4 (10.5)		
≥30	3 (1.16)	20 (1.55)	5 (3.23)	7 (18.42)		
Unknown/missing	0	0	0	0		
Maternal race (n [%])					0.18	0.05 (0.00–0.07)
Black	168 (64.9)	829 (64.4)	111 (71.6)	31 (81.6)		
White	71 (27.4)	339 (26.3)	32 (20.6)	5 (13.2)		
Other	20 (7.72)	119 (9.25)	12 (7.74)	2 (5.26)		
Unknown/missing	0	0	0	0		
Maternal education (years) (n [%])					0.14	0.05 (0.00–0.07)
Less than high school (≤9)	103 (39.8)	419 (32.6)	45 (29.0)	13 (34.2)		
High school (10-12)	137 (52.9)	730 (56.7)	95 (61.3)	22 (57.9)		
College and above (>12)	14 (5.41)	116 (9.01)	13 (8.39)	2 (5.26)		
Unknown/missing	5 (1.93)	22 (1.71)	2 (1.29)	1 (2.63)		
Marital status (n [%])					0.52	0.04 (0.00–0.06)
Single	120 (46.3)	602 (46.8)	77 (49.7)	19 (50.0)		
Married/common law	136 (52.5)	669 (52.0)	73 (47.1)	19 (50.0)		
Widowed/divorced/separated	3 (1.16)	16 (1.24)	5 (3.23)	0		
Unknown/missing	0	0	0	0		
Family income <sup>3</sup> (n [%])					0.10	0.05 (0.00–0.07)
≤\$1999	57 (22.0)	248 (19.3)	28 (18.1)	6 (15.8)		
\$2000-4999	121 (46.7)	626 (48.6)	71 (45.8)	18 (47.4)		
\$5000-7999	34 (13.1)	163 (12.7)	26 (16.8)	8 (21.1)		
≥\$8000	7 (2.70)	72 (5.59)	4 (2.58)	0		
Unknown/missing	40 (15.4)	178 (13.8)	26 (16.8)	6 (15.8)		
Socioeconomic index	3.6 (2.0, 5.0)	3.7 (2.3, 5.3)	3.7 (2.0, 5.3)	3.85 (2.55, 5.23)	0.25	0.05 (-0.001 to 0.10)
Socioeconomic index grouped (n [%])					0.65	0.04 (0.00–0.05)
0.0-1.9	48 (18.5)	185 (14.4)	27 (17.4)	5 (13.2)		
2.0-3.9	94 (36.3)	449 (34.9)	52 (33.5)	13 (34.2)		
4.0-5.9	61 (23.6)	366 (28.4)	45 (29.0)	13 (34.2)		
6.0-7.9	36 (13.9)	167 (13.0)	20 (12.9)	4 (10.5)		



8.0-9.5	11 (4.25)	88 (6.84)	9 (5.81)	1 (2.63)		
Unknown/missing	9 (3.47)	32 (2.49)	2 (1.29)	2 (5.26)		
Housing density (n [%])					0.67	0.03 (0.00–0.04)
<1 person	68 (26.3)	322 (25.0)	43 (27.7)	12 (31.6)		
1.0-3.0 people	177 (68.3)	898 (69.8)	108 (69.7)	25 (65.8)		
>3 people	8 (3.09)	40 (3.11)	3 (1.94)	0		
Other <sup>4</sup> /unknown/missing	6 (2.32)	27 (2.10)	1 (0.65)	1 (2.63)		
Smoking history <sup>5</sup> (n [%])					0.37	0.03 (0.00–0.05)
Non-smokers	150 (57.9)	733 (57.0)	88 (56.8)	23 (60.5)		
Light smokers (<1 pack per day)	85 (32.8)	452 (35.1)	53 (34.2)	14 (36.8)		
Heavy smokers (≥1 pack per day)	21 (8.11)	92 (7.15)	13 (8.39)	0		
Unknown/missing	3 (1.16)	10 (0.78)	1 (0.65)	1 (2.63)		
<b>Infant characteristics</b>						
Infant sex (n [%])					0.16	0.05 (0.00–0.09)
Male	140 (54.1)	676 (52.5)	68 (43.9)	22 (57.9)		
Female	119 (45.9)	611 (47.5)	87 (56.1)	16 (42.1)		
Gestational age (weeks)	34 (32, 36)	34 (32, 36)	34 (31, 36)	34 (29.8, 36)	0.56	-0.01 (-0.06 to 0.04)

Data are median (IQR; Kruskal-Wallis/Wilcoxon test for non-parametric data with Steel-Dwass *post-hoc*) for continuous variables, or n (%) (Likelihood Ratio Chi Square test) for categorical variables. \* $p < 0.05$ . Post hoc differences between groups are denoted by different letters. Effect sizes are Wilcoxon test effect size ( $r$ ) (95% CI) for continuous variables, or Cramer's V (95% CI) for categorical variables. <sup>1</sup>Weight gain recommendations based on Institute of Medicine (2009) guidelines for singleton pregnancies based on prepregnancy BMI. <sup>2</sup>Includes diabetes mellitus before pregnancy, during pregnancy, before and during pregnancy, during and post pregnancy, or before, during and post pregnancy. Does not include maternal diabetes mellitus during post partum period only. <sup>3</sup>\$1999, \$2000-4999, \$5000-7999, ≥\$8000 equivalent to \$17315, ≤\$17800, \$17801-\$44500, \$44501-\$71200, ≥\$71201 in 2020 US dollars, respectively. <sup>4</sup>Gravida in home for unwed mothers. <sup>5</sup>1 pack is 20 cigarettes. UW = underweight. NW = normal weight. OW = overweight. OB = obese.

**Supplementary Table 4.** Maternal characteristics by prepregnancy BMI in term pregnancies, N=10,415.

	Pregnancy BMI				p-value	Effect size
	UW (n=1201)	NW (n=8022)	OW (n=912)	OB (n=280)		
<b>Maternal characteristics</b>						
Prepregnancy BMI	17.8 (17.2, 18.1) <sup>A</sup>	21.0 (19.8, 22.3) <sup>B</sup>	26.5 (25.7, 27.6) <sup>C</sup>	32.0 (30.8, 34.4) <sup>D</sup>	<0.0001	0.58 (0.57–0.60)
Gestational weight gain max (lbs)	25 (20, 31) <sup>A</sup>	24 (18, 30) <sup>B</sup>	23 (15, 31) <sup>B</sup>	20 (13, 29) <sup>C</sup>	<0.0001	-0.05 (-0.07 to -0.03)
Gestational weight gain <sup>1</sup> (n [%])					<0.0001	0.21 (0.20–0.23)
Inadequate	749 (62.4)	4320 (53.9)	230 (25.2)	76 (27.1)		
Adequate	396 (33.0)	2803 (34.9)	316 (34.6)	81 (28.9)		
Excessive	54 (4.50)	868 (10.8)	361 (39.6)	122 (43.6)		
Unknown/missing	2 (0.17)	31 (0.39)	5 (0.55)	1 (0.36)		
Diabetes mellitus <sup>2</sup> (n [%])					0.27	0.02 (0.00–0.04)
Yes	13 (1.08)	48 (0.60)	7 (0.77)	3 (1.07)		
No	1181 (98.3)	7951 (99.1)	904 (99.1)	277 (98.9)		
Other/unknown/missing	7 (0.58)	23 (0.29)	1 (0.11)	0		
Maternal age (years)	19 (17, 21) <sup>A</sup>	19 (17, 22) <sup>B</sup>	20 (18, 22) <sup>C</sup>	21 (19, 25) <sup>D</sup>	<0.0001	0.05 (0.03–0.07)
Maternal age grouped (years) (n [%])					<0.0001	0.07 (0.06–0.08)
≤19	692 (57.6)	4138 (51.6)	430 (47.1)	90 (32.1)		
20-24	403 (33.6)	3035 (37.8)	351 (38.5)	119 (42.5)		
25-29	92 (7.66)	653 (8.14)	87 (9.54)	36 (12.9)		
≥30	14 (1.17)	196 (2.44)	44 (4.82)	35 (12.5)		
Missing	0	0	0	0		
Maternal race (n [%])					<0.0001	0.06 (0.04–0.07)
Black	528 (44.0)	3316 (41.3)	432 (47.4)	160 (57.1)		
White	546 (45.5)	4143 (51.6)	407 (44.7)	108 (38.6)		
Other	127 (10.6)	563 (7.02)	73 (7.92)	12 (4.29)		
Missing	0	0	0	0		
Maternal education (years) (n [%])					<0.0001	0.07 (0.05–0.08)
Less than high school (≤9)	327 (27.2)	1670 (20.8)	225 (24.7)	84 (30.0)		
High school (10-12)	663 (55.2)	4582 (57.1)	555 (60.9)	171 (61.1)		
College and above (>12)	202 (16.8)	1682 (21.0)	112 (12.3)	23 (8.21)		
Unknown/missing	9 (0.75)	88 (1.10)	20 (2.19)	2 (0.71)		
Marital status (n [%])					0.01	0.03 (0.008–0.04)
Single	389 (32.4)	2386 (29.7)	309 (33.9)	94 (33.6)		
Married/common law	785 (65.4)	5480 (68.3)	588 (64.5)	175 (62.5)		
Widowed/divorced/separated	27 (2.25)	156 (1.94)	15 (1.64)	11 (3.93)		
Unknown/missing	0	0	0	0		
Family income <sup>3</sup> (n [%])					0.007	0.03 (0.006–0.03)
≤\$1999	183 (15.2)	1205 (15.0)	145 (15.9)	44 (15.7)		
\$2000-4999	570 (47.5)	3580 (44.6)	416 (45.6)	138 (49.3)		
\$5000-7999	226 (18.8)	1556 (19.4)	178 (19.5)	61 (21.8)		
≥\$8000	93 (7.74)	809 (10.1)	71 (7.80)	13 (4.64)		
Unknown/missing	129 (10.7)	872 (10.9)	102 (11.2)	24 (8.57)		
Socioeconomic index	4.3 (3.0, 6.7) <sup>A</sup>	5.0 (3.3, 7.0) <sup>B</sup>	4.3 (3.0, 6.3) <sup>A</sup>	4.3 (2.7, 5.7) <sup>A</sup>	<0.0001	0.05 (0.03–0.07)
Socioeconomic index grouped (n [%])					<0.0001	0.06 (0.05–0.07)
0.0-1.9	126 (10.5)	672 (8.38)	85 (9.32)	28 (10.0)		
2.0-3.9	351 (29.2)	1994 (24.9)	278 (30.5)	85 (30.4)		
4.0-5.9	318 (26.5)	2100 (26.2)	263 (28.8)	98 (35.0)		
6.0-7.9	223 (18.6)	1779 (22.2)	181 (19.8)	46 (16.4)		

8.0-9.5	165 (13.7)	1344 (16.8)	76 (8.33)	11 (3.93)		
Unknown/missing	18 (1.50)	133 (1.66)	29 (3.18)	12 (4.29)		
Housing density (n [%])					<b>&lt;0.0001</b>	0.04 (0.02–0.05)
<1 person	342 (28.5)	2683 (33.4)	327 (35.9)	91 (32.5)		
1.0-3.0 people	820 (68.3)	5103 (63.6)	551 (60.4)	183 (65.4)		
>3 people	24 (2.00)	109 (1.36)	7 (0.77)	0		
Other <sup>4</sup> /unknown/missing	15 (1.25)	127 (1.58)	27 (2.96)	6 (2.14)		
Smoking history <sup>5</sup> (n [%])					0.11	0.02 (0.00–0.03)
Non-smokers	675 (56.2)	4758 (59.3)	531 (58.2)	161 (57.5)		
Light smokers (<1 pack per day)	392 (32.6)	2513 (31.3)	280 (30.7)	81 (28.9)		
Heavy smokers (≥1 pack per day)	130 (10.8)	722 (9.00)	97 (10.6)	34 (12.1)		
Unknown/missing	4 (0.33)	29 (0.36)	4 (0.44)	4 (1.43)		
<b>Infant characteristics</b>						
Infant sex (n [%])					0.56	0.01 (0.00–0.03)
Male	624 (52.0)	4124 (51.4)	476 (52.2)	133 (47.5)		
Female	577 (48.0)	3898 (48.6)	436 (47.8)	147 (52.5)		
Gestational age (weeks)	40 (39, 41) <sup>A</sup>	40 (39, 41) <sup>A</sup>	40 (39, 41) <sup>A</sup>	40 (39, 41) <sup>A</sup>	<b>0.03</b>	0.01 (-0.008 to 0.03)

Data are median (IQR; Kruskal-Wallis/Wilcoxon test for non-parametric data with Steel-Dwass *post-hoc* for continuous variables, or n (%) (Likelihood Ratio Chi Square test) for categorical variables. \*p<0.05. Post hoc differences between groups are denoted by different letters. Effect sizes are Wilcoxon test effect size (r) (95% CI) for continuous variables, or Cramer's V (95% CI) for categorical variables. <sup>1</sup>Weight gain recommendations based on Institute of Medicine (2009) guidelines for singleton pregnancies based on prepregnancy BMI. <sup>2</sup>Includes diabetes mellitus before pregnancy, during pregnancy, before and during pregnancy, during and post pregnancy, or before, during and post pregnancy. Does not include maternal diabetes mellitus during post partum period only. <sup>3</sup>\$1999, \$2000-4999, \$5000-7999, ≥\$8000 equivalent to \$17315, ≤\$17800, \$17801-\$44500, \$44501-\$71200, ≥\$71201 in 2020 US dollars, respectively. <sup>4</sup>Gravida in home for unwed mothers. <sup>5</sup>1 pack is 20 cigarettes. UW = underweight. NW = normal weight. OW = overweight. OB = obese.

**Supplementary Table 5.** Socioeconomic index (SES) stratified by study site.

Study Site Location	Institution	SES Index	p-value
Boston, MA	Lying-In Hospital Children's Medical Center	7.0 (5.3, 8.3) <sup>A</sup>	<b>&lt;0.0001</b>
Buffalo, NY	Children's Hospital, SUNY	8.3 (7.0, 9.3) <sup>B</sup>	
New Orleans, LA	Charity Hospital	3.0 (2.0, 4.0) <sup>C</sup>	
New York, NY	Columbia-Presbyterian	5.3 (4.0, 6.7) <sup>D</sup>	
Baltimore, MD	Johns Hopkins Hospital	3.3 (2.0, 5.0) <sup>C</sup>	
Richmond, VA	Medical College of Virginia	3.0 (2.0, 4.3) <sup>C</sup>	
Minneapolis, MN	University of Minnesota	7.0 (5.4, 8.3) <sup>E</sup>	
New York, NY	New York Medical College	4.0 (3.0, 5.3) <sup>F</sup>	
Portland, OR	University of Oregon Medical School	3.7 (2.7, 5.0) <sup>G</sup>	
Philadelphia, PA	Pennsylvania Hospital Children's Hospital of Philadelphia	3.7 (2.3, 5.0) <sup>CG</sup>	
Providence, RI	Providence Lying-In	4.7 (3.3, 6.3) <sup>H</sup>	
Memphis, TN	University of Tennessee College of Medicine	3.0 (2.0, 4.3) <sup>C</sup>	

Data are median (IQR; Kruskal-Wallis/Wilcoxon test for non-parametric data with Steel-Dwass *post-hoc*). \* $p < 0.05$ . Post hoc differences between groups are denoted by different letters.

**Supplementary Table 6.** Associations between maternal prepregnancy BMI and macroscopic placental pathologies in term pregnancies, N=10,415.

Placental pathology	Prepregnancy BMI				p-value	Effect size
	UW (n=1201)	NW (n=8022)	OW (n=912)	OB (n=280)		
<b>Placenta</b>						
Placenta shape					0.69	0.02 (0.00–0.02)
Non-partite	1059 (88.2)	7241 (90.3)	838 (91.9)	254 (90.7)		
Bipartite	14 (1.17)	107 (1.33)	8 (0.87)	4 (1.43)		
Tripartite	0	2 (0.02)	0	0		
Succenturiate	19 (1.58)	83 (1.03)	10 (1.10)	2 (0.71)		
Membranous placenta	0	1 (0.01)	1 (0.11)	0		
Crescent shaped	1 (0.08)	1 (0.01)	0	0		
Irregular shape	3 (0.25)	38 (0.47)	5 (0.55)	0		
Unknown/missing	105 (8.74)	549 (6.84)	50 (5.48)	20 (7.14)		
Weight (g)	400 (352, 455) <sup>A</sup>	420 (370, 480) <sup>B</sup>	440 (380, 500) <sup>C</sup>	447 (380, 500) <sup>BC</sup>	<0.0001	0.08 (0.06–0.10)
Largest diameter (cm)	19 (17, 20) <sup>A</sup>	19 (18, 20) <sup>B</sup>	19 (18, 20) <sup>C</sup>	19 (18, 20) <sup>BC</sup>	<0.0001	0.06 (0.04–0.08)
Smallest diameter (cm)	16 (15, 17) <sup>A</sup>	16 (15, 18) <sup>B</sup>	17 (15, 18) <sup>C</sup>	16.5 (15, 18) <sup>BC</sup>	<0.0001	0.05 (0.03–0.07)
Thickness (mm)	20 (20, 25)	20 (20, 25)	21 (20, 25)	20 (20, 25)	0.06	0.02 (0.0004–0.04)
Birthweight (g) : placenta weight (g)	7.60 (6.80, 8.41) <sup>A</sup>	7.46 (6.73, 8.29) <sup>A</sup>	7.32 (6.56, 8.12) <sup>B</sup>	7.29 (6.59, 8.25) <sup>AB</sup>	<0.0001	-0.03 (-0.05 to -0.006)
Birthweight (g) : placental largest diameter (cm)	164 (150, 179) <sup>A</sup>	167 (153, 182) <sup>B</sup>	169 (154, 183) <sup>B</sup>	167 (156, 185) <sup>B</sup>	<0.0001	0.05 (0.03–0.07)
Birthweight (g) : placental smallest diameter (cm)	190 (172, 210) <sup>A</sup>	193 (177, 212) <sup>B</sup>	195 (180, 214) <sup>B</sup>	195 (178, 214) <sup>B</sup>	<0.0001	0.04 (0.02–0.06)
Birthweight (g) : placental thickness (mm)	142 (123, 163) <sup>A</sup>	145 (127, 167) <sup>B</sup>	147 (128, 170) <sup>B</sup>	151 (129, 175) <sup>B</sup>	<0.0001	0.04 (0.02–0.06)
<b>Cord</b>						
Cord number of vessels					0.81	0.009 (0.00–0.02)
Two	7 (0.58)	51 (0.64)	4 (0.44)	1 (0.36)		
Three	1088 (90.6)	7421 (92.5)	857 (94.0)	258 (92.1)		
Other/unknown/missing	106 (8.83)	550 (6.86)	51 (5.59)	21 (7.50)		
Cord edema					0.34	0.02 (0.00–0.04)
Not seen	1059 (88.2)	7244 (90.3)	827 (90.7)	249 (88.9)		
Present	16 (1.33)	128 (1.60)	18 (1.97)	8 (2.86)		
Unknown/missing	126 (10.5)	650 (8.10)	67 (7.35)	23 (8.21)		
<b>Membranes and fetal surface</b>						
Opacity of membranes					0.05	0.03 (0.00–0.04)
Not opaque	1023 (85.2)	6982 (87.0)	786 (86.2)	241 (86.1)		
Partially opaque	0	12 (0.15)	4 (0.44)	0		
Opaque	70 (5.8)	479 (5.97)	73 (8.0)	17 (6.07)		
Unknown/missing	108 (8.99)	549 (6.84)	49 (5.37)	22 (7.86)		
Thrombosed fetal vessels					0.02	0.03 (0.004–0.05)
Not seen	1096 (91.3)	7457 (93.0)	860 (94.3)	257 (91.8)		
Present	0	23 (0.29)	3 (0.33)	3 (1.06)		
Unknown/missing	105 (8.74)	542 (6.76)	49 (5.37)	20 (7.09)		
<b>Cut surface</b>						
Infarct size					0.44	0.02 (0.00–0.03)
Not applicable	817 (68.0)	5445 (67.9)	615 (67.4)	182 (65.0)		
All infarcts < 3 cms	238 (19.8)	1721 (21.5)	218 (23.9)	67 (23.9)		

>1 infarct measures $\geq 3$ cm	35 (2.9)	283 (3.53)	28 (3.07)	10 (3.57)		
Unknown/missing	111 (9.24)	573 (7.14)	51 (5.59)	21 (7.50)		
Cut surface calcification					0.20	0.02 (0.00–0.03)
None	461 (38.4)	2992 (37.3)	336 (36.8)	122 (43.6)		
Maternal surface only	473 (39.4)	3339 (41.6)	382 (41.9)	104 (37.1)		
Calcification throughout	158 (13.2)	1112 (13.9)	144 (15.8)	33 (11.8)		
Unknown/missing	109 (9.08)	579 (7.22)	50 (5.48)	21 (7.50)		

Data are median (IQR; Kruskal-Wallis/Wilcoxon test for non-parametric data with Steel-Dwass *post-hoc*) for continuous variables or n (%) (Likelihood Ratio Chi Square test) for categorical variables. \* $p < 0.05$ . Post hoc differences between groups are denoted by different letters. Effect sizes are Wilcoxon test effect size ( $r$ ) (95% CI) for continuous variables, and Cramer's  $V$  (95% CI) for categorical variables. UW = underweight. NW = normal weight. OW = overweight. OB = obese.

**Supplementary Table 7.** Multivariable analyses for associations between maternal prepregnancy BMI (continuous) and macroscopic placental pathologies in term pregnancies, N=10,415.

Placental pathology	Unadjusted model			Adjusted model		
	$\beta$ (95% CI)	OR (95% CI)	p-value	$\beta$ (95% CI)	OR (95% CI)	p-value
<b>Placenta</b>						
Weight (g)	2.84 (2.33–3.36)	-	****	3.71 (3.18–4.25)	-	****
Largest diameter (cm)	0.04 (0.03–0.06)	-	****	0.06 (0.04–0.07)	-	****
Smallest diameter (cm)	0.04 (0.03–0.05)	-	****	0.05 (0.03, 0.06)	-	****
Thickness (mm)	0.007 (-0.02 to 0.03)	-	NS	0.05 (0.02, 0.07)	-	***
Birthweight (g) : placenta weight (g)	-0.02 (-0.03 to -0.02)	-	****	-0.02 (-0.03 to -0.02)	-	****
Birthweight (g) : placental largest diameter (cm)	0.20 (0.07–0.33)	-	**	0.43 (0.30–0.57)	-	****
Birthweight (g) : placental smallest diameter (cm)	0.28 (0.11–0.44)	-	***	0.56 (0.39–0.73)	-	****
Birthweight (g) : placental thickness (mm)	0.55 (0.35–0.76)	-	****	0.56 (0.34–0.77)	-	****
<b>Cord</b>						
Cord number of vessels	-0.02 (-0.10 to 0.06)	0.98 (0.90–1.06)	NS	-0.03 (-0.12 to 0.06)	0.97 (0.89–1.06)	NS
Two						
Three						
Cord edema	0.03 (-0.01 to 0.07)	1.03 (0.99–1.07)	NS	0.02 (-0.03 to 0.07)	1.02 (0.97–1.07)	NS
Not seen						
Present						
<b>Membranes and fetal surface</b>						
Opacity of membranes	0.02 (-0.002 to 0.04)	1.02 (1.00–1.05)	NS	0.02 (-0.008 to 0.04)	1.02 (0.99–1.04)	NS
Not opaque						
Any degree of opacity						
Thrombosed fetal vessels	0.06 (-0.02 to 0.15)	1.07 (0.98–1.16)	NS	0.05 (-0.06 to 0.16)	1.05 (0.94–1.18)	NS
Not seen						
Present						
<b>Cut surface</b>						
Infarcts	0.02 (0.006–0.03)	1.02 (1.01–1.03)	**	0.03 (0.02–0.04)	1.03 (1.02–1.05)	****
Not applicable						
Any infarcts seen						
Cut surface calcification	-0.004 (-0.02 to 0.009)	1.00 (0.98–1.01)	NS	0.002 (-0.01 to 0.02)	1.00 (0.99–1.02)	NS
None						
Any calcification seen						

Data are  $\beta$  (95% CI) and unit odds ratios (95% CI) for presence of pathology from Logistic regression models with p-value from Likelihood Ratio Chi Square test for categorical variables, or  $\beta$  (95% CI) with p-value from Standard Least Squares models for continuous variables. The adjusted model includes fetal sex, maternal race, maternal age, smoking history, maternal education, socioeconomic status, gestational weight gain, and maternal diabetes mellitus status. NS (not significant):  $p > 0.05$ ; \* $p \leq 0.05$ ; \*\* $p \leq 0.01$ ; \*\*\* $p \leq 0.001$ ; \*\*\*\* $p \leq 0.0001$ .

**Supplementary Table 8.** Associations between maternal prepregnancy BMI and macroscopic placental pathologies in preterm pregnancies, N=1739.

Placental pathology	Prepregnancy BMI				p-value	Effect size
	UW (n=259)	NW (n=1287)	OW (n=155)	OB (n=38)		
<b>Placenta</b>						
Placenta shape					0.43	0.04 (0.00–0.04)
Non-partite	219 (84.6)	1135 (88.2)	142 (91.6)	35 (92.1)		
Bipartite	0	5 (0.39)	0	0		
Tripartite	0	0	0	0		
Succenturiate	5 (1.9)	16 (1.24)	1 (0.65)	1 (2.63)		
Membranous placenta	0	0	0	0		
Crescent shaped	0	0	0	0		
Irregular shape	0	7 (0.54)	0	0		
Unknown/missing	35 (13.5)	124 (9.63)	12 (7.74)	2 (5.26)		
Weight (g)	360 (310, 425) <sup>A</sup>	380 (320, 440) <sup>AB</sup>	405 (330, 470) <sup>B</sup>	440 (360, 501) <sup>B</sup>	<b>0.0008</b>	0.04 (-0.004 to 0.09)
Largest diameter (cm)	18 (16, 19) <sup>A</sup>	18 (17, 19) <sup>A</sup>	18 (17, 20) <sup>A</sup>	19 (16, 21) <sup>A</sup>	<b>0.05</b>	0.05 (-0.001 to 0.10)
Smallest diameter (cm)	15 (14, 17) <sup>A</sup>	16 (14, 17) <sup>AB</sup>	16 (14, 17) <sup>AB</sup>	17 (15, 18) <sup>B</sup>	<b>0.005</b>	0.06 (0.01–0.11)
Thickness (mm)	20 (18, 25)	20 (18, 23)	20 (18, 25)	20 (19.3, 25)	0.77	-0.0006 (-0.05 to 0.05)
Birthweight (g) : placenta weight (g)	7.34 (6.49, 8.31)	7.22 (6.45, 8.11)	7.21 (6.41, 7.91)	6.99 (6.21, 8.26)	0.49	-0.03 (-0.07 to 0.02)
Birthweight (g) : placental largest diameter (cm)	151 (138, 167)	154 (136, 170)	158 (140, 173)	163 (146, 177)	0.23	0.02 (-0.03 to 0.06)
Birthweight (g) : placental smallest diameter (cm)	174 (161, 195)	178 (159, 198)	180 (162, 204)	183 (171, 204)	0.52	0.02 (-0.04 to 0.06)
Birthweight (g) : placental thickness (mm)	134 (115, 156)	135 (117, 159)	140 (119, 159)	147 (119, 170)	0.23	0.03 (-0.02 to 0.08)
<b>Cord</b>						
Cord number of vessels					0.79	0.02 (0.00–0.05)
Two	1 (0.39)	10 (0.78)	1 (0.65)	0		
Three	223 (86.1)	1154 (89.7)	143 (92.3)	37 (97.4)		
Other/unknown/missing	35 (13.5)	123 (9.56)	11 (7.10)	1 (2.63)		
Cord edema					0.11	0.06 (0.00–0.11)
Not seen	218 (84.2)	1099 (85.4)	131 (84.5)	33 (86.8)		
Present	5 (1.93)	50 (3.89)	10 (6.45)	3 (7.89)		
Unknown/missing	36 (13.9)	138 (10.7)	14 (9.03)	2 (5.26)		
<b>Membranes and fetal surface</b>						
Opacity of membranes					0.28	0.06 (0.00–0.09)
Not opaque	208 (80.3)	1078 (83.8)	129 (83.2)	32 (84.2)		
Partially opaque	0	0	1 (0.65)	0		
Opaque	15 (5.79)	86 (6.68)	14 (9.03)	5 (13.2)		
Unknown/missing	36 (13.9)	123 (9.56)	11 (7.10)	1 (2.63)		
Thrombosed fetal vessels					0.26	0.05 (0.00–0.09)
Not seen	221 (85.3)	1160 (90.1)	141 (91.0)	37 (97.4)		
Present	3 (1.16)	7 (0.54)	3 (1.94)	0		
Unknown/missing	35 (13.5)	120 (9.32)	11 (7.10)	1 (2.63)		
<b>Cut Surface</b>						
Infarct size					0.95	0.02 (0.00–0.02)
Not applicable	178 (68.7)	936 (72.7)	111 (71.6)	28 (73.7)		
All infarcts < 3 cms	34 (13.1)	191 (14.9)	28 (18.1)	7 (18.4)		
At least one infarct measures ≥3 cms	9 (3.47)	39 (3.03)	5 (3.23)	1 (2.63)		



Unknown/missing	38 (14.7)	121 (9.40)	11 (7.10)	2 (5.26)		
Cut surface calcification					0.74	0.03 (0.00–0.05)
None	119 (45.9)	638 (49.6)	85 (54.8)	16 (42.1)		
Maternal surface only	78 (30.1)	396 (30.8)	42 (27.1)	14 (36.8)		
Calcification throughout	25 (9.65)	129 (10.0)	17 (11.0)	6 (15.8)		
Unknown/missing	37 (14.3)	124 (9.63)	11 (7.10)	2 (5.26)		


Data are median (IQR; Kruskal-Wallis/Wilcoxon test for non-parametric data with Steel-Dwass *post-hoc*) for continuous variables or n (%) (Likelihood Ratio Chi Square test) for categorical variables. \*p<0.05. Post hoc differences between groups are denoted by different letters. Effect sizes are Wilcoxon test effect size (r) (95% CI) for continuous variables, or Cramer's V (95% CI) for categorical variables. UW = underweight. NW = normal weight. OW = overweight. OB = obese.

**Supplementary Table 9.** Multivariable analyses for associations between maternal prepregnancy BMI (continuous) and macroscopic placental pathologies in preterm pregnancies, N=1739.

Placental pathology	Unadjusted model			Adjusted model		
	$\beta$ (95% CI)	OR (95% CI)	p-value	$\beta$ (95% CI)	OR (95% CI)	p-value
<b>Placenta</b>						
Weight (g)	3.26 (1.80–4.73)	-	****	3.25 (1.72–4.77)	-	****
Largest diameter (cm)	0.05 (0.01–0.08)	-	**	0.04 (0.01–0.08)	-	**
Smallest diameter (cm)	0.06 (0.03–0.09)	-	***	0.06 (0.03–0.09)	-	***
Thickness (mm)	0.05 (-0.02 to 0.11)	-	NS	0.06 (-0.007 to 0.13)	-	NS
Birthweight (g) : placenta weight (g)	-0.02 (-0.04 to 0.006)	-	NS	-0.01 (-0.04 to 0.02)	-	NS
Birthweight (g) : placental largest diameter (cm)	0.62 (0.22–1.02)	-	**	0.87 (0.45–1.29)	-	****
Birthweight (g) : placental smallest diameter (cm)	0.37 (-0.11 to 0.85)	-	NS	0.67 (0.15–1.18)	-	**
Birthweight (g) : placental thickness (mm)	0.53 (-0.04 to 1.10)	-	NS	0.49 (-0.12 to 1.10)	-	NS
<b>Cord</b>						
Cord number of vessels	0.03 (-0.14 to 0.19)	1.03 (0.87–1.21)	NS	0.04 (-0.13 to 0.22)	1.04 (0.88–1.24)	NS
Two						
Three						
Cord edema	0.07 (0.003–0.13)	1.07 (1.00–1.14)	NS	0.04 (-0.03 to 0.11)	1.04 (0.97–1.12)	NS
Not seen						
Present						
<b>Membranes and fetal surface</b>						
Opacity of membranes	0.05 (0.005–0.10)	1.06 (1.01–1.11)	*	0.05 (-0.007 to 0.11)	1.05 (0.99–1.11)	NS
Not opaque						
Any degree of opacity						
Thrombosed fetal vessels	0.04 (-0.12 to 0.19)	1.04 (0.89 to 1.20)	NS	0.02 (-0.14 to 0.18)	1.02 (0.87–1.19)	NS
Not seen						
Present						
<b>Cut Surface</b>						
Infarcts	0.03 (-0.005 to 0.07)	1.03 (1.00–1.07)	NS	0.03 (-0.006 to 0.08)	1.04 (0.99–1.08)	NS
Not applicable						
Any infarcts seen						
Cut surface calcification	-0.002 (-0.03 to 0.03)	1.00 (0.97–1.03)	NS	-0.009 (-0.04 to 0.02)	0.99 (0.96–1.03)	NS
None						
Any calcification seen						

Data are  $\beta$  (95% CI) and unit odds ratios (95% CI) for presence of pathology from Logistic regression models with p-value from Likelihood Ratio Chi Square test for categorical variables, or  $\beta$  (95% CI) with p-value from Standard Least Squares models for continuous variables. The adjusted model includes fetal sex, maternal race, maternal age, smoking history, maternal education, socioeconomic status, gestational weight gain, and maternal diabetes mellitus status. NS (not significant);  $p > 0.05$ ; \* $p \leq 0.05$ ; \*\* $p \leq 0.01$ ; \*\*\* $p \leq 0.001$ ; \*\*\*\* $p \leq 0.0001$ .

## Supplementary figures




Supplementary Figure 1. Participant flow selection and placental pathologies of interest.

**A**


	Year (date of delivery)								
	1959	1960	1961	1962	1963	1964	1965	1966	p-value
<b>Maternal BMI</b>	21.3 (19.5, 23.2)	20.9 (19.4, 22.7)	21.0 (19.4, 22.9)	20.9 (19.4, 22.9)	20.9 (19.4, 22.7)	21.0 (19.5, 23.0)	21.0 (19.6, 22.9)	20.9 (19.5, 22.8)	0.10

**B**



Supplementary Figure 2. Maternal prepregnancy BMI (continuous) across study years (based on date of delivery). There were no differences in maternal BMI (continuous) stratified by year of delivery. Data are (A) median (IQR; Kruskal-Wallis/Wilcoxon test), and (B) scatter plot with line of fit.

A



B

Neutrophil infiltration	Preterm		OR (95% CI)	p-value	Term		OR (95% CI)	p-value
	Male (n=22)	Female (n=16)			Male (n=133)	Female (n=147)		
Umbilical vein			1.00 (0.22, 4.56)	NS			2.01 (0.99, 4.11)	0.05
Not seen	15 (68.2)	12 (75.0)			106 (79.3)	130 (88.4)		
Any degree	5 (22.7)	4 (25.0)			23 (17.8)	14 (9.52)		
Unknown/missing	2 (9.09)	0			6 (2.96)	3 (2.04)		
Umbilical artery			0.76 (0.13, 4.43)	NS			0.83 (0.28, 2.46)	NS
Not seen	17 (77.3)	13 (81.3)			123 (91.9)	136 (92.5)		
Any degree	3 (13.6)	3 (18.8)			6 (5.19)	8 (5.44)		
Unknown/missing	2 (9.09)	0			4 (2.96)	3 (2.04)		
Umbilical cord substance			1.08 (0.20, 5.73)	NS			1.91 (0.76, 4.76)	NS
Not seen	16 (72.7)	13 (81.3)			116 (86.7)	136 (92.5)		
Any degree	4 (18.2)	3 (18.8)			13 (10.4)	8 (5.44)		
Unknown/missing	2 (9.09)	0			4 (2.96)	3 (2.04)		
Amnion membrane			2.33 (0.39, 14.0)	NS			1.47 (0.72, 3.02)	NS
Not seen	15 (68.2)	14 (87.5)			106 (79.3)	117 (79.6)		
Any degree	5 (22.7)	2 (12.5)			20 (15.6)	15 (10.2)		
Unknown/missing	2 (9.09)	0			7 (5.19)	15 (10.2)		
Chorion membrane			1.86 (0.38, 9.00)	NS			1.77 (0.98, 3.19)	0.06
Not seen	14 (63.6)	13 (81.3)			96 (71.1)	120 (81.6)		
Any degree	6 (27.3)	3 (18.8)			34 (26.7)	24 (16.3)		
Unknown/missing	2 (9.09)	0			3 (2.22)	3 (2.04)		
Amnion placenta			0.82 (0.10, 6.62)	NS			1.80 (0.72, 4.50)	NS
Not seen	17 (77.3)	14 (87.5)			112 (83.7)	124 (84.4)		
Any degree	2 (9.09)	2 (12.5)			13 (10.4)	8 (5.44)		
Unknown/missing	3 (13.6)	0			8 (5.93)	15 (10.2)		
Chorion placenta			2.33 (0.39, 14.0)	NS			1.56 (0.76, 3.20)	NS
Not seen	15 (68.2)	14 (87.5)			110 (81.5)	129 (87.8)		
Any degree	5 (22.7)	2 (12.5)			20 (16.3)	15 (10.2)		
Unknown/missing	2 (9.09)	0			3 (2.22)	3 (2.04)		

Supplementary Figure 3. Placental neutrophil infiltration in pregnancies with maternal obesity by fetal sex, n=318. Presence or absence of neutrophil infiltration for female and male placentae among pregnancies with maternal obesity by preterm (male: n=22, female: n=16) and term (male: n=133, female: n=147) birth. Data are n (%) (Likelihood Ratio Chi Square test) and odds ratio (95% CI) for presence of pathology in male placentae.